Jawed Fareed - Publications

Affiliations: 
Loyola University Chicago, Chicago, IL, United States 
Area:
Pharmacology, Cell Biology

469 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bontekoe J, Bansal V, Lee J, Syed M, Hoppensteadt D, Maia P, Walborn A, Liles J, Vasaiwala S, Fareed J. Procalcitonin as a Marker of Comorbid Atrial Fibrillation in Chronic Kidney Disease and History of Sepsis. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 26: 1076029620932228. PMID 32539447 DOI: 10.1177/1076029620932228  0.314
2020 Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, ... ... Fareed J, et al. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis. PMID 32473596 DOI: 10.1055/S-0040-1713152  0.321
2020 Walborn A, Rondina M, Fareed J, Hoppensteadt D. Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 26: 1076029620902849. PMID 32129085 DOI: 10.1177/1076029620902849  0.301
2020 Phan T, Brailovsky Y, Fareed J, Hoppensteadt D, Iqbal O, Darki A. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 26: 1076029619900549. PMID 31960711 DOI: 10.1177/1076029619900549  0.307
2020 Farooqui A, Hoppensteadt D, Iqbal O, Bacher C, Lewis M, Walenga J, Kouta A, Jeske W, Fareed J. Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Antiheparin Platelet Factor 4 Antibodies as Studied in Platelet Aggregation Assays The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05681  0.773
2020 Venkitasubramony V, Polisky A, Siddiqui F, Kouta A, Fareed J, Hoppensteadt D, Iqbal O, Laddu A, Jeske W. Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04049  0.31
2020 Bacher C, Farooqui A, Siddiqui F, Daravath B, Hoppensteadt D, Iqbal O, Fareed J, George M, Thiel DV. Liver Diseases Contribute to Functional Platelet Aggregation Defects The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03485  0.755
2019 Kouta A, Jeske W, Hoppensteadt D, Iqbal O, Yao Y, Fareed J. Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 25: 1076029619889406. PMID 31793333 DOI: 10.1177/1076029619889406  0.381
2019 Mendes A, Meneghetti MCZ, Palladino MV, Justo GZ, Sassaki GL, Fareed J, Lima MA, Nader HB. Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants. Molecules (Basel, Switzerland). 24. PMID 31426507 DOI: 10.3390/Molecules24162988  0.319
2019 Monakhova YB, Fareed J, Yao Y, Diehl BWK. Anticoagulant activity of porcine heparin: Structural-property relationship and semi-quantitative estimation by nuclear magnetic resonance (NMR) spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 174: 639-643. PMID 31279893 DOI: 10.1016/J.Jpba.2019.06.036  0.328
2019 Walborn A, Rondina M, Mosier M, Fareed J, Hoppensteadt D. Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 25: 1076029619852163. PMID 31140293 DOI: 10.1177/1076029619852163  0.323
2019 Patel P, Walborn A, Rondina M, Fareed J, Hoppensteadt D. Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 25: 1076029619843338. PMID 30991817 DOI: 10.1177/1076029619843338  0.308
2019 Kouta A, Jeske W, Duff R, Hoppensteadt D, Iqbal O, Fareed J. USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels Blood. 134: 165-165. DOI: 10.1182/Blood-2019-131943  0.323
2019 Farooqui A, Hoppensteadt D, Iqbal O, Bacher C, Walenga J, Kouta A, Jeske W, Lewis B, Fareed J. Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies Blood. 134: 2446-2446. DOI: 10.1182/Blood-2019-131825  0.358
2019 Hoppensteadt D, Bontekoe E, Siddiqui F, Farooqui A, Iqbal O, Jeske W, Walenga J, Tafur AJ, Fareed J. Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma Blood. 134: 3374-3374. DOI: 10.1182/Blood-2019-131221  0.314
2019 Antic D, Milic N, Otasevic V, Salak TV, Djurasinovic V, Vukovic V, Tomic K, Mihaljevic B, Fareed J. Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR) and Risk of Thromboembolism in Patients with Lymphoma Blood. 134: 3649-3649. DOI: 10.1182/Blood-2019-130073  0.306
2019 Kalodiki E, Wexels F, Dahl O, Walenga J, Jeske W, Iqbal O, Hoppensteadt D, Fareed J. In Vivo and Ex Vivo Thrombin Generation in Noncomorbid Patients with Suspected Deep Venous Thrombosis Journal of Vascular Surgery. Venous and Lymphatic Disorders. 7: 291-292. DOI: 10.1016/J.Jvsv.2019.01.014  0.307
2018 Lee J, McMillan R, Skiadopoulos L, Bansal V, Biller J, Hoppensteadt D, Fareed J. Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618811090. PMID 30428695 DOI: 10.1177/1076029618811090  0.302
2018 Bontekoe J, Lee J, Bansal V, Syed M, Hoppensteadt D, Maia P, Walborn A, Liles J, Brailovsky E, Fareed J. Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiopoietin-2 and Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618808909. PMID 30370780 DOI: 10.1177/1076029618808909  0.3
2018 Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, Elalamy I, Gerotziafas GT, Hoppensteadt D. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618806424. PMID 30296833 DOI: 10.1177/1076029618806424  0.393
2018 Jeske W, Kouta A, Duff R, Rangnekar V, Niverthi M, Hoppensteadt D, Fareed J, Yao Y. Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618798956. PMID 30198315 DOI: 10.1177/1076029618798956  0.392
2018 Statz S, Sabal G, Walborn A, Williams M, Hoppensteadt D, Mosier M, Rondina M, Fareed J. Angiopoietin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618786029. PMID 29996658 DOI: 10.1177/1076029618786029  0.301
2018 Walborn A, Williams M, Fareed J, Hoppensteadt D. International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618772353. PMID 29848060 DOI: 10.1177/1076029618772353  0.34
2018 Tanaka K, Tawara S, Tsuruta K, Hoppensteadt D, Fareed J. Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618770274. PMID 29683037 DOI: 10.1177/1076029618770274  0.323
2018 Jabati S, Fareed J, Liles J, Otto A, Hoppensteadt D, Bontekoe J, Phan T, Walborn A, Syed M. Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618761006. PMID 29558818 DOI: 10.1177/1076029618761006  0.301
2017 Xu Y, Chandarajoti K, Zhang X, Pagadala V, Dou W, Hoppensteadt DM, Sparkenbaugh EM, Cooley B, Daily S, Key NS, Severynse-Stevens D, Fareed J, Linhardt RJ, Pawlinski R, Liu J. Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. Science Translational Medicine. 9. PMID 28878012 DOI: 10.1126/Scitranslmed.Aan5954  0.34
2017 Wanderling C, Liles J, Finkler E, Carlsgaard P, Hopkinson W, Guler N, Hoppensteadt D, Fareed J. Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029617700998. PMID 28345356 DOI: 10.1177/1076029617700998  0.335
2017 Sweigert PJ, Bansal VK, Hoppensteadt DA, Saluk JL, Syed DA, Fareed J. Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease. The International Journal of Angiology : Official Publication of the International College of Angiology, Inc. 26: 43-48. PMID 28255215 DOI: 10.1055/S-0036-1593409  0.302
2017 Bertini S, Fareed J, Madaschi L, Risi G, Torri G, Naggi A. Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029616685430. PMID 28118750 DOI: 10.1177/1076029616685430  0.361
2017 Liu X, St Ange K, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Chi L, Jin C, Jin Y, Yao Y, Linhardt RJ. Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029616686422. PMID 28056526 DOI: 10.1177/1076029616686422  0.319
2017 Sadeghi N, Siddiqui Z, Iqbal O, Abro S, Hoppensteadt D, Mosier M, Walenga J, Fareed J, Kouta A. Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence Blood. 130: 4868-4868. DOI: 10.1182/Blood.V130.Suppl_1.4868.4868  0.378
2016 Indran T, Alsarraj MK, Fareed J, Walenga J, Jeske W, Hoppensteadt D, Iqbal O, Bakhos M. Comparative studies on the anticoagulant and antiprotease activity of bovine, ovine and porcine heparins. Pathology. 48: S99. PMID 27773217 DOI: 10.1016/J.Pathol.2015.12.281  0.34
2016 Guler N, Abro S, Emanuele M, Iqbal O, Hoppensteadt D, Fareed J. The Protective Effect of Poloxamer-188 on Platelet Functions. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. PMID 27651174 DOI: 10.1177/1076029616669785  0.314
2016 Sadeghi N, Iacobelli M, Vaziri B, Kahn D, Hoppensteadt D, Guler N, Fareed J. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates: Studies on the Comparison of NovoSeven With a Biosimilar Product. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. PMID 27553841 DOI: 10.1177/1076029616663848  0.34
2016 Liles J, Liles J, Wanderling C, Syed M, Hoppensteadt D, Fareed J. Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. PMID 27170781 DOI: 10.1177/1076029616648407  0.342
2016 St Ange K, Onishi A, Fu L, Sun X, Lin L, Mori D, Zhang F, Dordick JS, Fareed J, Hoppensteadt D, Jeske W, Linhardt RJ. Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. PMID 27084870 DOI: 10.1177/1076029616643822  0.309
2016 Abro S, Clark M, Barkan G, Hoppensteadt D, Fareed J, Wojick E, Quek M. Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 22: 314-21. PMID 26685219 DOI: 10.1177/1076029615622000  0.309
2016 Walborn A, Patel P, Hoppensteadt D, Mosier M, Rondina MT, Fareed J. Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis Associated Coagulopathy Blood. 128: 564-564. DOI: 10.1182/Blood.V128.22.564.564  0.336
2016 Bouchard O, Hoppensteadt D, Maia P, Castro ASd, Kumar E, Guler N, Jeske W, Kahn D, Walenga JM, Coyne E, Yao Y, Fareed J. Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives Are Comparable in Contrast to Their Bovine Equivalents Blood. 128: 5027-5027. DOI: 10.1182/Blood.V128.22.5027.5027  0.304
2016 Gerotziafas GT, Dreden PV, Jeske W, Walenga JM, Hoppensteadt D, Larsen A, Elalamy I, Yao Y, Fareed J. Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays Blood. 128: 5020-5020. DOI: 10.1182/Blood.V128.22.5020.5020  0.405
2016 Siddiqui Z, Aggarwal P, Iqbal O, Hoppensteadt D, Lewis M, Abro S, Tsuruta K, Fareed J. Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications Blood. 128: 4974-4974. DOI: 10.1182/Blood.V128.22.4974.4974  0.393
2016 Liles J, Wanderling C, Otto AM, Liles J, Hoppensteadt D, Syed D, Jabati S, Syed M, Fareed J. Persistent Prothrombotic State in Atrial Fibrillation Despite Use of Novel Oral Anti-Coagulants Blood. 128: 3832-3832. DOI: 10.1182/Blood.V128.22.3832.3832  0.347
2016 Siddiqui Z, Iqbal O, Hoppensteadt D, Lewis M, Rege R, Abro S, Fareed J. Dabigatran Neutralizing Antobody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications Blood. 128: 2622-2622. DOI: 10.1182/Blood.V128.22.2622.2622  0.341
2016 Patel P, Walborn A, Hoppensteadt D, Mosier M, Rondina MT, Fareed J. Biomarkers of Inflammation and Infection in Sepsis Associated Disseminated Intravascular Coagulation and Their Prognostic Role Blood. 128: 1412-1412. DOI: 10.1182/Blood.V128.22.1412.1412  0.338
2016 Emanuele N, Hoppensteadt D, Wanderling C, Carlsgaard P, Truitt E, Hopkinson W, Fareed J. Effect of Recombinant Lubricin on Human Blood Coagulation Parameters and Platelet Aggregation The Faseb Journal. 30. DOI: 10.1096/Fasebj.30.1_Supplement.Lb458  0.315
2016 Hoppensteadt D, Kalodiki E, Maia P, Castro ASd, Kumar E, Guler N, Jeske W, Kahn D, Walenga J, Coyne E, Fareed J. Resourcing of Heparin and Low-Molecular-Weight Heparins from Bovine, Ovine, and Porcine Origin: Studies to Demonstrate the Biosimilarities Journal of Vascular Surgery. Venous and Lymphatic Disorders. 4: 150. DOI: 10.1016/J.Jvsv.2015.10.042  0.312
2015 Gerotziafas GT, Rouseau A, Mbemba E, Khartechi A, Van Dreden P, Walenga J, Fareed J, Elalamy I. Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 21: 697-704. PMID 26023170 DOI: 10.1177/1076029615587355  0.309
2015 Halaris A, Myint AM, Savant V, Meresh E, Lim E, Guillemin G, Hoppensteadt D, Fareed J, Sinacore J. Does escitalopram reduce neurotoxicity in major depression? Journal of Psychiatric Research. 66: 118-26. PMID 26009299 DOI: 10.1016/J.Jpsychires.2015.04.026  0.302
2015 Richards J, Bansal V, Iqbal O, Hoppensteadt D, Fareed J. Immunoenzymatic and biochip array profiling of the biomarkers of inflammation and hemostatic activation processes in ESRD. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 21: 405-11. PMID 25753964 DOI: 10.1177/1076029615575073  0.322
2015 Lattimer CR, Kalodiki E, Geroulakos G, Syed D, Hoppensteadt D, Fareed J. d-Dimer Levels are Significantly Increased in Blood Taken From Varicose Veins Compared With Antecubital Blood From the Same Patient. Angiology. 66: 882-8. PMID 25561693 DOI: 10.1177/0003319714565168  0.313
2015 Sadeghi N, O'Malley P, Kahn D, Hoppensteadt D, Fareed J. A Generic Version of Recombinant FVIIa Is Similar to the Branded Product (NovoSeven) Blood. 126: 4746-4746. DOI: 10.1182/Blood.V126.23.4746.4746  0.342
2015 Hoppensteadt D, Maia P, Silva A, Kumar E, Guler N, Jeske W, Kahn D, Walenga JM, Coyne E, Fareed J. Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities Blood. 126: 4733-4733. DOI: 10.1182/Blood.V126.23.4733.4733  0.425
2015 Liles JP, Wanderling C, Liles JL, Hoppensteadt D, Fareed J, Syed D, Syed M. Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs Blood. 126: 4731-4731. DOI: 10.1182/Blood.V126.23.4731.4731  0.342
2015 Hoppensteadt D, Williams M, Syed D, Guler N, Mosier M, Fareed J. Baseline Thrombin Generation Markers and Functional Antithrombin Levels in Sepsis Associated Coagulopathies Are Predictive of the Severity of Pathogenesis Blood. 126: 4693-4693. DOI: 10.1182/Blood.V126.23.4693.4693  0.3
2015 McMillan R, Bansal V, Skiadopoulos L, Hoppensteadt D, Iqbal O, Parasuraman R, Guler N, Fareed J. Role of Platelet Activation in the Pathogenesis of Heart Failure in End-Stage Renal Disease Patients Blood. 126: 4636-4636. DOI: 10.1182/Blood.V126.23.4636.4636  0.383
2015 Fareed J, Bansal V, Syed D, Hoppensteadt D, Guler N. Upregulation of Microparticles, Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin in End Stage Renal Disease Blood. 126: 2312-2312. DOI: 10.1182/Blood.V126.23.2312.2312  0.311
2015 Fareed J, Hoppensteadt D, Syed D, Kahn D, Mosier M, Walborn A, Williams M. Recombinant Thrombomodulin Inhibits Tissue Factor Mediated Thrombin Generation in Blood Plasma and Is Modulated By Prothrombin Complex Concentrates Blood. 126: 2303-2303. DOI: 10.1182/Blood.V126.23.2303.2303  0.367
2015 Hesselton AK, Mosier M, Hoppensteadt D, Jeske W, Fareed J. Cellular and Functional Characterization of Microparticles in Sepsis-Associated Coagulopathy Blood. 126: 2297-2297. DOI: 10.1182/Blood.V126.23.2297.2297  0.37
2015 Walborn A, Kahn D, Hoppensteadt D, Fareed J. Biomarkers of Hemostatic Dysregulation, Inflammation, and Infection in Patients Diagnosed with Sepsis Associated Coagulopathy Blood. 126: 2281-2281. DOI: 10.1182/Blood.V126.23.2281.2281  0.368
2015 Guler N, Abro S, Emanuele M, Iqbal O, Hoppensteadt D, Fareed J. Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188 ) As Studied in Agonist Induced Platelet Aggregation Systems Blood. 126: 1037-1037. DOI: 10.1182/Blood.V126.23.1037.1037  0.35
2014 Walenga JM, Kaiser PC, Prechel MM, Hoppensteadt D, Jeske WP, Misselwitz F, Bacher P, Lassen MR, Fareed J. Sustained release of tissue factor following thrombosis of lower limb trauma. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 20: 678-86. PMID 25115761 DOI: 10.1177/1076029614545212  0.328
2014 Sadeghi N, Kahn D, Syed D, Iqbal O, Abro S, Eshraghi R, Hoppensteadt D, Fareed J. Comparative biochemical and functional studies on a branded human recombinant factor viia and a biosimilar equivalent product Clinical and Applied Thrombosis/Hemostasis. 20: 565-572. PMID 24651302 DOI: 10.1177/1076029614527496  0.312
2014 Sadeghi N, Kahn D, Sayed D, Hoppenstadt D, Jeske W, Harenberg J, Dechristopher P, Fareed J. Compositional differences in commercially available prothrombin complex concentrates Clinical and Applied Thrombosis/Hemostasis. 20: 256-269. PMID 24288386 DOI: 10.1182/Blood.V120.21.4391.4391  0.339
2014 Hoppensteadt D, Tsuruta K, Cunanan J, Hirman J, Kaul I, Osawa Y, Fareed J. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 20: 129-35. PMID 23804232 DOI: 10.1182/Blood.V120.21.1131.1131  0.325
2014 Hoppensteadt DA, Gray A, Jeske WP, Walenga JM, Fareed J. Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 20: 621-8. PMID 23482722 DOI: 10.1177/1076029613480556  0.334
2014 Gerotziafas GT, Galea V, Mbemba E, Sassi M, Roman MP, Khaterchi A, van Dreden P, Japcowitz M, Lotz JP, Bernaudin JF, Fareed J, Hatmi M, Elalamy I. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3. Current Vascular Pharmacology. 12: 893-902. PMID 22724467 DOI: 10.2174/157016111206141210121441  0.405
2014 Wahi R, Kalodiki E, Lakhanpal S, Rai A, Fareed J. Review paper The role of sulodexide in chronic venous insufficiency Pattern Recognition. 22: 1-5. DOI: 10.5114/Pr.2014.46046  0.309
2014 Sadeghi N, Kahn D, Hoppensteadt D, Eshraghi R, Fareed J. Recombinant Factor VIIa (rFVIIa) Mediated Activation of Prothrombin Complex Concentrates (PCCs). Studies on the Comparison of Novoseven with a Biosimilar Product Blood. 124: 5108-5108. DOI: 10.1182/Blood.V124.21.5108.5108  0.339
2014 Gerotziafas GT, Dreden PV, Rousseau A, Khaterchi A, Walenga JM, Fareed J, Elalamy I. Use of Thrombin Generation Assay As Tool for the Evaluation of the Antithrombotic Samenesse of Enoxaparine Copies Blood. 124: 5092-5092. DOI: 10.1182/Blood.V124.21.5092.5092  0.386
2014 Hoppensteadt D, Syed D, Jezovnik M, Poredos P, Tetik S, Iqbal O, Walenga JM, Fareed J. Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban Blood. 124: 5084-5084. DOI: 10.1182/Blood.V124.21.5084.5084  0.368
2014 Dansdill D, Cho J, Syed D, Fareed J, Emanuele M. Augmentation of the Anticoagulant Effects of Heparin By a Tri-Block Polymer MST-188 Blood. 124: 5080-5080. DOI: 10.1182/Blood.V124.21.5080.5080  0.373
2014 Sayani S, Iqbal O, Hoppensteadt D, Fareed J. Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs Blood. 124: 4267-4267. DOI: 10.1182/Blood.V124.21.4267.4267  0.362
2014 Hoppensteadt D, Goldford M, Bisset A, Syed D, Zuckerman L, Jeske W, Harenberg J, Fareed J. Validation Studies on Coagulation Laboratory Assays Useful for Assessing the Plasma Levels of Apixaban Blood. 124: 2866-2866. DOI: 10.1182/Blood.V124.21.2866.2866  0.318
2014 Fareed J, Hoppensteadt D, Emanuele M, Syed D, Schuharazad A, Jeske W, Wahi R. Procoagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and Their Modulation By a Triblock Polymer MST 188 Blood. 124: 2816-2816. DOI: 10.1182/Blood.V124.21.2816.2816  0.315
2014 Hoppensteadt D, Kola J, Brayne M, Iqbal O, Fareed J. Usefulness of Dilute Russell’s Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants Blood. 124: 1537-1537. DOI: 10.1182/Blood.V124.21.1537.1537  0.324
2013 Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, ... ... Fareed J, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Critical Care Medicine. 41: 2069-79. PMID 23979365 DOI: 10.1097/CCM.0b013e31828e9b03  0.324
2013 Nicolaides A, Hull RD, Fareed J. Prevention and treatment of venous thromboembolism: International consensus statement (Guidelines according to scientific evidence) Clinical and Applied Thrombosis/Hemostasis. 19: 116-225. PMID 23529476 DOI: 10.1177/1076029612474840  0.314
2013 Kaneva K, Bansal V, Hoppensteadt D, Cunanan J, Fareed J. Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 19: 449-52. PMID 23463188 DOI: 10.1177/1076029613479820  0.363
2013 Sadeghi N, Kahn D, Jeske W, Hoppensteadt D, Fareed J. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: Potential clinical implication Clinical and Applied Thrombosis/Hemostasis. 19: 589-599. PMID 23463187 DOI: 10.1177/1076029613479819  0.366
2013 Lima MA, Viskov C, Herman F, Gray AL, de Farias EH, Cavalheiro RP, Sassaki GL, Hoppensteadt D, Fareed J, Nader HB. Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities. Thrombosis and Haemostasis. 109: 471-8. PMID 23329070 DOI: 10.1160/Th12-11-0795  0.306
2013 Walenga JM, Jeske WP, Hoppensteadt D, Cunanan J, Khan H, Escalante V, Fareed J, Bakhos M. Comparative studies on branded enoxaparin and a US generic version of enoxaparin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 19: 261-7. PMID 23091283 DOI: 10.1182/Blood.V120.21.2264.2264  0.365
2013 Hoppensteadt D, Kahn D, Harenberg J, Fareed J. Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates Blood. 122: 4810-4810. DOI: 10.1182/Blood.V122.21.4810.4810  0.366
2013 Fareed J, Moorman MJ, Jeske W, Hoppensteadt D. Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs Blood. 122: 4804-4804. DOI: 10.1182/Blood.V122.21.4804.4804  0.41
2013 Bansal V, Hoppensteadt D, Ahmed S, Fareed J. Dysregulation Of Thrombotic and Hemostatic Factors In End Stage Renal Disease Blood. 122: 4793-4793. DOI: 10.1182/Blood.V122.21.4793.4793  0.348
2013 Fareed J, Hoppensteadt D, Iqbal O, Abro S, Emanuele M. Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation Blood. 122: 4770-4770. DOI: 10.1182/Blood.V122.21.4770.4770  0.344
2013 Hoppensteadt D, Emanuele M, Molnar J, Iqbal O, Fareed J. Effect Of Purified Poloxamer 188 and Various Dextrans On Erythrocyte Sedimentation Rate In Healthy Subjects and Patients With Sickle Cell Disease Blood. 122: 4764-4764. DOI: 10.1182/Blood.V122.21.4764.4764  0.325
2013 Jeske W, Escalante V, McGuire B, Walenga JM, Fareed J, Bakhos M. Neutralization Of Hemorrhage Induced By Direct Factor Xa and Thrombin Inhibitors In a Rat Model Blood. 122: 3644-3644. DOI: 10.1182/Blood.V122.21.3644.3644  0.322
2013 Hoppensteadt D, Walenga JM, Cunanan J, Iqbal O, Fareed J. Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants Blood. 122: 3642-3642. DOI: 10.1182/Blood.V122.21.3642.3642  0.353
2013 Cunanan J, Lewis BE, Fareed J. Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications Blood. 122: 3641-3641. DOI: 10.1182/Blood.V122.21.3641.3641  0.355
2013 Walenga JM, Matsuo T, Wanaka K, Cunanan J, Hoppensteadt D, Fareed J. Thrombotic Biomarker Profiling Of Plasma Samples From Patients Undergoing Bypass Surgery Using Protein Chip Array Blood. 122: 3579-3579. DOI: 10.1182/Blood.V122.21.3579.3579  0.408
2013 Syed D, Mosier M, Malalis J, Mata C, Lin A, Mitchel N, Abro S, Hoppensteadt D, Fareed J, Bouchard C. Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis Blood. 122: 1117-1117. DOI: 10.1182/Blood.V122.21.1117.1117  0.305
2012 Bouças RI, Jarrouge-Bouças TR, Lima MA, Trindade ES, Moraes FA, Cavalheiro RP, Tersariol IL, Hoppenstead D, Fareed J, Nader HB. Glycosaminoglycan backbone is not required for the modulation of hemostasis: effect of different heparin derivatives and non-glycosaminoglycan analogs. Matrix Biology : Journal of the International Society For Matrix Biology. 31: 308-16. PMID 22504459 DOI: 10.1016/J.Matbio.2012.03.001  0.344
2012 Sadeghi N, Zhu H, Setty SK, Cunanan J, Hoppensteadt D, Fareed J. Cross-reactivity of various thrombin products with anti-rabbit antibodies to bovine, human, and recombinant thrombin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 18: 243-8. PMID 22345489 DOI: 10.1177/1076029611425829  0.302
2012 Gray A, Litinas E, Jeske W, Fareed J, Hoppensteadt D. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 18: 166-73. PMID 22311630 DOI: 10.1177/1076029611421167  0.37
2012 Jeske W, Litinas E, Khan H, Hoppensteadt D, Fareed J. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 18: 294-8. PMID 22275388 DOI: 10.1177/1076029611432138  0.33
2012 Thethi I, Lewis B, Fareed J. Oral factor Xa and direct thrombin inhibitors: a clinical perspective. Journal of Burn Care & Research : Official Publication of the American Burn Association. 33: 453-61. PMID 22269826 DOI: 10.1097/Bcr.0B013E318248Bc4C  0.321
2012 Cohen M, Jeske WP, Nicolau JC, Montalescot G, Fareed J. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. Journal of Thrombosis and Thrombolysis. 33: 230-8. PMID 22234748 DOI: 10.1007/S11239-012-0680-3  0.33
2012 Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annual Review of Pharmacology and Toxicology. 52: 79-99. PMID 21819239 DOI: 10.1146/Annurev-Pharmtox-010611-134633  0.315
2012 Clark M, Quek ML, Kahn D, Hoppensteadt D, Cunanan J, Fareed J. Biomarker profiling of bladder cancer patients undergoing radical cystectomy: Relevance of thrombotic and inflammatory processes. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15008  0.3
2012 Fareed J, Gray A, Kahn D, Cunanan J, Khan H, Viskov C, Hoppensteadt D. The effect of tissue factor pathway inhibitor release and interactions with growth factors on the antitumor effects of ultra low molecular weight heparin semuloparin. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E13117  0.337
2012 Masood S, Hoppensteadt D, Cunanan J, Khan H, Abro S, Bartosiak K, Fareed J. Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs Blood. 120: 3421-3421. DOI: 10.1182/Blood.V120.21.3421.3421  0.38
2012 Bansal V, Kaneva K, Hoppensteadt D, Cunanan J, Fareed J. Variations in the Circulating Heparin Levels During Maintenance Hemodialysis in End Stage Renal Disease Patients Blood. 120: 3412-3412. DOI: 10.1182/Blood.V120.21.3412.3412  0.365
2012 Fareed J, Hoppensteadt D, Iqbal O, Cunanan J, Bansal V, Abro S, Wahi R. Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents Blood. 120: 3411-3411. DOI: 10.1182/Blood.V120.21.3411.3411  0.4
2012 Fareed J, Sadeghi N, Kahn D, Cunanan J, Bartosiak K, Harenberg J, Hoppensteadt D. Tissue Factor Mediated Activation of Prothrombin Complex Concentrates (PCCs) Is Differently Inhibited by Dabigatran, Rivaroxaban and Apixaban. Potential Clinical Implications Blood. 120: 3410-3410. DOI: 10.1182/Blood.V120.21.3410.3410  0.382
2012 Abro S, Clark M, Quek M, Iqbal O, Kahn D, Hoppensteadt D, Cunanan J, Fareed J. Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes Blood. 120: 3405-3405. DOI: 10.1182/Blood.V120.21.3405.3405  0.342
2012 Jeske W, Walenga JM, Escalante V, Hoppensteadt D, Cunanan J, Kahn D, Akhras A, Paulus M, Fareed J, Bakhos M. Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins Blood. 120: 1172-1172. DOI: 10.1182/Blood.V120.21.1172.1172  0.355
2012 Gerotziafas G, Roman MP, Mdemba E, Hatmi M, Fareed J, Bernaudin JF, Elalamy I. Semuloparin Efficiently Inhibits Thrombin Generation Triggered by Pancreas Adenocarcinoma Cells BXPC3. Distinct Roles of Anti-XA and Anti-IIA Activity Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)34255-1  0.386
2011 Davis R, Bansal V, Litinas E, Hoppensteadt D, Thethi I, Nelson K, Fareed J. Upregulation of inflammatory mediators in end-stage renal disease as measured using biochip array technology. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 17: E218-23. PMID 21873362 DOI: 10.1177/1076029610397752  0.311
2011 Paterson CA, Pixton GC, Proskin HM, Massaro JM, Morasch M, Cronstein B, Fareed J, Ofosu FA. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 17: 620-32. PMID 21596694 DOI: 10.1177/1076029611405187  0.326
2011 Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Thrombosis Research. 128: 361-7. PMID 21458847 DOI: 10.1016/J.Thromres.2011.03.001  0.308
2011 Fareed J, Adiguzel C, Thethi I. Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thrombosis Journal. 9: 5. PMID 21443789 DOI: 10.1186/1477-9560-9-5  0.33
2011 Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. Seminars in Thrombosis and Hemostasis. 37: 141-5. PMID 21370215 DOI: 10.1055/S-0030-1270341  0.306
2011 Jeske WP, Walenga JM, Samama MM, Hoppensteadt D, Mayuga M, Fareed J. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 22: 206-10. PMID 21297455 DOI: 10.1097/Mbc.0B013E328343F859  0.339
2011 Kalodiki E, Fareed J. New and generic anticoagulants and biosimilars: safety considerations. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 17: 136-9. PMID 21159711 DOI: 10.1177/1076029610387128  0.35
2011 Bhandari M, Ofosu FA, Mackman N, Jackson C, Doria C, Humphries JE, Babu SC, Ortel TL, Hoffman Van Thiel D, Walenga JM, Wahi R, Teoh KH, Fareed J. Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 17: 39-45. PMID 21078609 DOI: 10.1177/1076029610385674  0.326
2011 Fareed J, Jeske W, Hoppensteadt D, Wahi R, Hull RD. Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma Blood. 118: 4328-4328. DOI: 10.1182/Blood.V118.21.4328.4328  0.346
2011 Jeske W, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Rigal H, Bayol A, Viskov C. Biological Activities of Two Ultra-Low Molecular Weight Heparins, Semuloparin and Bemiparin, Reveal That a Common Potency Standard Is Inadequate Blood. 118: 4324-4324. DOI: 10.1182/Blood.V118.21.4324.4324  0.409
2011 Fareed J, Wahi R, Thethi I, Hoppensteadt D, Bansal V, Walenga JM, Messmore HL. Molecular Mimicry in the Adulteration of Heparins. Chemical Basis for the Development of Oversulfated Chondroitin Sulfate and Related Contaminants Blood. 118: 4322-4322. DOI: 10.1182/Blood.V118.21.4322.4322  0.34
2011 Hoppensteadt D, Cunanan J, Khan H, Litinas E, Sharma G, Kaul I, Fareed J. Thrombin Generation Mediators and Markers in Sepsis Associated Coagulapathy Blood. 118: 3341-3341. DOI: 10.1182/Blood.V118.21.3341.3341  0.337
2011 Lewis BE, Aranda C, Lewis M, Hoppensteadt D, Walenga JM, Fareed J. Unlike Heparins Newer Oral Anticoagulants Do Not Interact with HIT Antibodies and Maybe Useful in the Longterm Anticoagulant Management of Heparin Compromised Patients Blood. 118: 2317-2317. DOI: 10.1182/Blood.V118.21.2317.2317  0.426
2011 Rahman S, Hoppensteadt D, Cunanan J, Davis R, Sadeghi N, Kaul I, Fareed J. Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation Blood. 118: 2302-2302. DOI: 10.1182/Blood.V118.21.2302.2302  0.316
2011 Hoppensteadt D, Khan H, Thethi I, Demir M, Adiguzel C, Rahman S, Fareed J. Inflammatory and Thrombotic Mediators in Small Cell Lung Carcinoma: Potential Role in Thromboembolic Complications Blood. 118: 2294-2294. DOI: 10.1182/Blood.V118.21.2294.2294  0.323
2011 Walenga JM, Aranda C, Linhardt R, Liu J, Lewis M, Hoppensteadt D, Fareed J. Comparative Studies on the HIT Antibody Mediated Platelet Aggregation / Serotonin Release by Synthetic Pentasaccharide and Two Chemoenzymatically Synthesized Heptasaccharides Blood. 118: 2231-2231. DOI: 10.1182/Blood.V118.21.2231.2231  0.395
2011 Jeske W, Litinas E, Khan H, Hoppensteadt D, McGeehan E, Fareed J. Comparison of the Pharmacokinetic and Pharmacodynamic Behavior of Branded and Generic Enoxaparin in Non-Human Primates Blood. 118: 1254-1254. DOI: 10.1182/Blood.V118.21.1254.1254  0.374
2011 Hoppensteadt D, Jeske W, Gray A, Walenga JM, Wahi R, Thethi I, Fareed J. Pharmacodynamic Differences in the Two Generic Brands of Enoxaparin Blood. 118: 1251-1251. DOI: 10.1182/Blood.V118.21.1251.1251  0.354
2011 Fareed J, Hoppensteadt D, Ottman A, Iqbal O, Jeske W, Gray A, Walenga JM, Kalodiki E, Thethi I, Wahi R. Product Associated Variation in Generic Enoxaparin. Potential Clinical Implications Blood. 118: 1249-1249. DOI: 10.1182/Blood.V118.21.1249.1249  0.301
2011 Sharma G, Bijlani R, Litinas E, Hoppensteadt D, Cunanan J, Khan H, Sharma G, Kaul I, Fareed J. Identification of Unique Biomarkers in Sepsis Associated Coagulopathy Blood. 118: 1237-1237. DOI: 10.1182/Blood.V118.21.1237.1237  0.325
2011 Gray A, Litinas E, Hoppensteadt D, Cunanan J, Lewis BE, Iqbal O, Fareed J. Thrombin Generation Inhibition by Newer Anti Xa and Anti IIa Drugs in Prothrombin Complex Concentrates: Relevance to Endogenous Modulation of Thrombogenesis Blood. 118: 1196-1196. DOI: 10.1182/Blood.V118.21.1196.1196  0.378
2011 Lima MA, De Farias EHC, Rudd TR, Ebner LF, Gesteira TF, Mendes A, Bouas RI, Martins JRM, Hoppensteadt D, Fareed J, Yates EA, Sassaki GL, Tersariol ILS, Nader HB. Low molecular weight heparins: Structural differentiation by spectroscopic and multivariate approaches Carbohydrate Polymers. 85: 903-909. DOI: 10.1016/J.Carbpol.2011.04.021  0.319
2010 Jeske WP, Fareed J, Hoppensteadt DA, Lewis B, Walenga JM. Pharmacology of argatroban. Expert Review of Hematology. 3: 527-39. PMID 21083469 DOI: 10.1586/Ehm.10.53  0.367
2010 He Zhu, Hoppensteadt D, Morris M, Fareed J. Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 16: 522-8. PMID 20699260 DOI: 10.1177/1076029610375423  0.306
2010 Mousa SA, Jeske WP, Fareed J. Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist. Methods in Molecular Biology (Clifton, N.J.). 663: 221-8. PMID 20617420 DOI: 10.1007/978-1-60761-803-4_8  0.36
2010 Fareed J, Hoppensteadt DA, Ramacciotti E, Hull RD. Contaminants in heparins: are all facts known? Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 16: 242-3. PMID 20547552 DOI: 10.1177/1076029610365507  0.376
2010 Kuziej J, Litinas E, Hoppensteadt DA, Liu D, Walenga JM, Fareed J, Jeske W. In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative Clinical and Applied Thrombosis-Hemostasis. 16: 377-386. PMID 20460347 DOI: 10.1177/1076029610366439  0.39
2010 Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clinical and Applied Thrombosis-Hemostasis. 16: 170-176. PMID 20299391 DOI: 10.1177/1076029609355589  0.348
2010 Genzen JR, Fareed J, Hoppensteadt D, Kurup V, Barash P, Coady M, Wu YY. Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion. 50: 801-7. PMID 20003049 DOI: 10.1111/J.1537-2995.2009.02531.X  0.361
2010 Hoppensteadt DA, Neville B, Schultz C, Jeske W, Raake W, Fareed J. Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 16: 13-20. PMID 19959490 DOI: 10.1177/1076029609345688  0.371
2010 Fareed J, Litinas E, Hoppensteadt D, Thethi I, Bansal V. Upregulation of Von Willebrand Factor, Von Wilelbrand Factor Propeptide, and ADMATS-13 In End-Stage Renal Disease Blood. 116: 5189-5189. DOI: 10.1182/Blood.V116.21.5189.5189  0.321
2010 Bansal V, Davis R, Litinas E, Hoppensteadt D, Thethi I, Fareed J. Upregulation of Inflammatory Mediators In End-Stage Renal Disease as Measured Via Biochip Array Technology Blood. 116: 5186-5186. DOI: 10.1182/Blood.V116.21.5186.5186  0.314
2010 Sharain K, Davis R, Hoppensteadt D, Cunanan J, Litinas E, Bansal V, Fareed J. Activation Markers of Thrombogenesis and Endothelial Dysfunction In End-Stage Renal Disease Blood. 116: 5183-5183. DOI: 10.1182/Blood.V116.21.5183.5183  0.318
2010 Aranda C, Hoppensteadt D, Iqbal O, Lewis BE, Fareed J. Differential Inhibition of Arachidonic Acid Mediated Aggregation of Platelets by Branded and Generic Argatroban Preparations Blood. 116: 5131-5131. DOI: 10.1182/Blood.V116.21.5131.5131  0.368
2010 Fareed J, Hoppensteadt D, Iqbal O, Walenga JM, Lewis BE. Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays Blood. 116: 5129-5129. DOI: 10.1182/Blood.V116.21.5129.5129  0.365
2010 Sadeghi N, Cunanan J, Hoppensteadt D, Thethi I, Wahi R, Fareed J. Cross Reactivity of Rabbit Anti-Recothrom (Human Recombinant Thrombin) Antibodies with Molecular Variants of Human Thrombin, and Various Bovine Thrombin Preparations Blood. 116: 4418-4418. DOI: 10.1182/Blood.V116.21.4418.4418  0.313
2010 Hoppensteadt D, Gray A, Cunanan J, Jeske W, Walenga JM, Fareed J. Comparative Studies on An Anti-Xa Enriched Ultra Low Molecular Weight Heparin with Bemiparin Blood. 116: 4394-4394. DOI: 10.1182/Blood.V116.21.4394.4394  0.399
2010 Jeske W, McAllister RE, Walenga JM, Paulus M, Fareed J. Effect of Heparin:PMX60056 Complexes on Platelet Aggregation Induced by ADP or HIT Antibody Blood. 116: 4386-4386. DOI: 10.1182/Blood.V116.21.4386.4386  0.387
2010 Jeske W, McGeehan E, Iqbal O, Hoppensteadt D, Walenga JM, Fareed J. Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox) Blood. 116: 4385-4385. DOI: 10.1182/Blood.V116.21.4385.4385  0.384
2010 Song C, Cunanan J, Kahn H, Hoppensteadt D, Fareed J. Differential Prevalence of Anti-Heparin-Platelet Factor 4 Antibodies In Elderly Patients with Acute Hip Fracture Undergoing Orthopaedic Surgery and Anticoagulated with Unfractionated Heparin and Enoxaparin Blood. 116: 4217-4217. DOI: 10.1182/Blood.V116.21.4217.4217  0.375
2010 Hoppensteadt D, Cunanan J, Sadeghi N, Kaul I, Fareed J. Dysregulation of Inflammatory and Hemostatic Markers In Disseminated Intravascular Coagulation. Blood. 116: 3656-3656. DOI: 10.1182/Blood.V116.21.3656.3656  0.31
2010 Gerotziafas GT, Sassi M, Galea V, Fareed J, Walenga JM, Elalamy I. Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs Blood. 116: 3334-3334. DOI: 10.1182/Blood.V116.21.3334.3334  0.397
2010 Paterson C, Pixton G, Proskin H, Massaro J, Morasch M, Fareed J, Ofosu F, Cronstein B. Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis Blood. 116: 1401-1401. DOI: 10.1182/Blood.V116.21.1401.1401  0.304
2010 Galea V, Gerotziafas GT, Sassi M, Fareed J, Walenga JM, Elalamy I. Comparison of Seven Generic Enoxaparins with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia. Blood. 116: 1105-1105. DOI: 10.1182/Blood.V116.21.1105.1105  0.363
2010 Hoppensteadt D, Jeske W, Litinas E, Iqbal O, Walenga JM, Lewis BE, Kahn H, Fareed J. Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome. Blood. 116: 1098-1098. DOI: 10.1182/Blood.V116.21.1098.1098  0.391
2010 Walenga JM, Hoppensteadt D, Litinas E, Messmore HL, Lewis BE, Rao G, Hull R, Fareed J. Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects. Blood. 116: 1091-1091. DOI: 10.1182/Blood.V116.21.1091.1091  0.357
2009 Adiguzel C, Iqbal O, Demir M, Fareed J. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 15: 645-651. PMID 19850586 DOI: 10.1177/1076029609339748  0.326
2009 Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, Iacobelli M. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 20: 627-34. PMID 19809307 DOI: 10.1097/Mbc.0B013E32832Da1E3  0.335
2009 Erez O, Gotsch F, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, Kim CJ, Chaiworapongsa T, Hoppensteadt D, Fareed J, Than NG, Nhan-Chang CL, Yeo L, Pacora P, Mazor M, Hassan SS, et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death Journal of Maternal-Fetal & Neonatal Medicine. 22: 672-687. PMID 19736615 DOI: 10.1080/14767050902853117  0.313
2009 Adiguzel C, Iqbal O, Hoppensteadt D, Jeske W, Cunanan J, Litinas E, Zhu H, Walenga JM, Fareed J. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Clinical and Applied Thrombosis-Hemostasis. 15: 501-511. PMID 19703818 DOI: 10.1177/1076029609338711  0.379
2009 Viskov C, Bouley E, Hubert P, Martinez C, Herman F, Jeske W, Hoppensteadt D, Walenga J, Fareed J. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Clinical and Applied Thrombosis-Hemostasis. 15: 395-401. PMID 19617248 DOI: 10.1177/1076029609338710  0.324
2009 Kannan M, Saxena R, Adiguzel C, Fareed J. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. Seminars in Thrombosis and Hemostasis. 35: 337-43. PMID 19452409 DOI: 10.1055/S-0029-1222612  0.379
2009 Li B, Suwan J, Martin JG, Zhang F, Zhang Z, Hoppensteadt D, Clark M, Fareed J, Linhardt RJ. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochemical Pharmacology. 78: 292-300. PMID 19389385 DOI: 10.1016/J.Bcp.2009.04.012  0.332
2009 Adiguzel C, Bansal V, Litinas E, Cunanan J, Iqbal O, Nelson K, Kannan M, Hoppensteadt D, Fareed J. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 15: 145-51. PMID 19357103 DOI: 10.1177/1076029609332802  0.346
2009 Adiguzel C, Jeske WP, Hoppensteadt D, Walenga JM, Bansal V, Fareed J. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Clinical and Applied Thrombosis-Hemostasis. 15: 137-144. PMID 19357102 DOI: 10.1177/1076029609332727  0.33
2009 Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J, Mismetti P, Ofosu FA, Raake W, Samama M, Schulman S. Recommendations on biosimilar low-molecular-weight heparins. Journal of Thrombosis and Haemostasis : Jth. 7: 1222-5. PMID 19323788 DOI: 10.1111/J.1538-7836.2009.03349.X  0.312
2009 Cella G, Vianello F, Cozzi F, Marotta H, Tona F, Saggiorato G, Iqbal O, Fareed J. Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to Connective Tissue Diseases The Journal of Rheumatology. 36: 760-767. PMID 19208592 DOI: 10.3899/Jrheum.080542  0.304
2009 Zhu H, Hoppensteadt D, Adiguzel C, Bick RL, Fareed J. Comparison of Immunogenic Potentials of Bovine Thrombin Preparations Clinical and Applied Thrombosis-Hemostasis. 15: 41-49. PMID 19117966 DOI: 10.1177/1076029608327863  0.302
2009 Zhu H, Hoppensteadt D, Wahi R, Cunanan J, Adiguzel C, Bick RL, Fareed J. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 15: 32-40. PMID 18977777 DOI: 10.1177/1076029608322550  0.306
2009 Kannan M, Ahmad F, Saxena R, Fareed J. Higher Prevalence of Heparin-Induced Thrombocytopenia Antibodies in Asian Indian Population: Is This Due to Contaminated Heparin? Blood. 114: 4182-4182. DOI: 10.1182/Blood.V114.22.4182.4182  0.336
2009 Fareed J, Hoppensteadt D, Cunanan J, Jeske W, Adiguzal C, Zhu H, Echart C, Iacobelli M. Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs. Blood. 114: 4180-4180. DOI: 10.1182/Blood.V114.22.4180.4180  0.321
2009 Gerotziafas GT, Vasso G, Walenga JM, Kalodiki E, Chaari M, Mohamed H, Fareed J, Ismail E. Thrombin Generation Assessment in Platelet Rich Plasma Offers Additional Criteria for Low Molecular Weight Heparin Antithrombotic Fingerprint Characterization. Blood. 114: 4177-4177. DOI: 10.1182/Blood.V114.22.4177.4177  0.41
2009 Hoppensteadt D, Gray A, Litinas E, Kaiser B, Fareed J. Pharmacodynamic Differences of An Anti-Xa Enriched Low Molecular Weight Heparin, AVE 5026 in Comparison to Enoxaparin and Unfractionated Heparin. Blood. 114: 4171-4171. DOI: 10.1182/Blood.V114.22.4171.4171  0.397
2009 Clark M, Sadeghi N, Hoppensteadt D, Myers L, Bansal V, Ramacciotti E, Fareed J. Protease Generation by Chondroitin Sulfate, Semisynthetic OSCS Preparations and Contaminants Isolated From Heparin. Blood. 114: 3133-3133. DOI: 10.1182/Blood.V114.22.3133.3133  0.339
2009 Jeske W, Masse N, Emanuele J, Zhu H, McGeehan E, Fareed J, Bakhos M, Walenga JM. Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications. Blood. 114: 3128-3128. DOI: 10.1182/Blood.V114.22.3128.3128  0.336
2009 Iqbal O, Plamoottil G, Sadeghi N, Hoppensteadt D, Fareed J. Oversulfated Chondroitin Sulfate Does Not Cause Augmentation in HIT Antibody Mediated Heparin-Induced Platelet Aggregation (HIPA). Blood. 114: 2417-2417. DOI: 10.1182/Blood.V114.22.2417.2417  0.415
2009 Iqbal O, Sadeghi N, Bakhos F, Hoppensteadt D, Fareed J. Gender-Based Differences in Hemostatic Responses. Implications in Effective Anticoagulant Management. Blood. 114: 2103-2103. DOI: 10.1182/Blood.V114.22.2103.2103  0.331
2009 Litinas E, Gray A, Sadeghi N, Cunanan J, Hoppensteadt D, Fareed J. Persistant Inhibition of Thrombin Generation After Intravenous Administration of Enoxaparin in Primates. Blood. 114: 2095-2095. DOI: 10.1182/Blood.V114.22.2095.2095  0.39
2009 Fareed J, Zhu H, Cunanan J, Jeske W, Hoppensteadt D, Arif H, Harry M, Walenga JM. Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation. Blood. 114: 2094-2094. DOI: 10.1182/Blood.V114.22.2094.2094  0.361
2009 Zeimys J, Hoppensteadt D, VanThiel D, George M, Iqbal O, Fareed J. Comparative Studies On Heparin Contaminant Interactions with Normals, Liver Disease, Heparin Treated and Oral Anticoagulant Treated Patients Plasma. Blood. 114: 2093-2093. DOI: 10.1182/Blood.V114.22.2093.2093  0.353
2009 Fareed J, Ramacciotti E, Hoppensteadt D, Sadeghi N, Hussain A, VanThiel D, George M. Oversulfated Chondroitin Sulfate Is Not the Sole Contaminant in Recalled Heparin Preparations. Blood. 114: 1070-1070. DOI: 10.1182/Blood.V114.22.1070.1070  0.366
2009 Fareed J, Clark M, Bansal V, Myers L, Iqbal O, Hoppensteadt D, Ramacciotti E, Walenga JM. Contaminants Isolated From Recalled Heparin Are Not All the Same: Clinical Implications. Blood. 114: 1069-1069. DOI: 10.1182/Blood.V114.22.1069.1069  0.356
2008 Fareed J, Jeske W, Fareed D, Clark M, Wahi R, Adiguzel C, Hoppensteadt D. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 14: 385-92. PMID 18815137 DOI: 10.1177/1076029608319881  0.352
2008 Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. American Journal of Cardiology. 102: 842-846. PMID 18805108 DOI: 10.1016/J.Amjcard.2008.05.025  0.371
2008 Hoppensteadt DA, Wahi R, Adiguzel C, Iqbal O, Ramacciotti E, Bick RL, Messmore HL, Bansal V, Fareed J. Contaminant in the recalled unfractionated heparin preparations: where is the problem? Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 14: 261-6. PMID 18565985 DOI: 10.1177/1076029608317932  0.329
2008 Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Seminars in Thrombosis and Hemostasis. 34: 74-85. PMID 18393144 DOI: 10.1055/S-2008-1066026  0.337
2008 Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Seminars in Thrombosis and Hemostasis. 34: 58-73. PMID 18393143 DOI: 10.1055/S-2008-1066025  0.352
2008 Hoppensteadt DA, Jeske W, Walenga J, Fareed J. The future of anticoagulation. Seminars in Respiratory and Critical Care Medicine. 29: 90. PMID 18302091 DOI: 10.1055/S-2008-1047567  0.321
2008 Fareed J, Bick RL, Rao G, Goldhaber SZ, Sasahara A, Messmore HL, Happensteadt DA, Nicolaides A. The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products Clinical and Applied Thrombosis/Hemostasis. 14: 5-7. PMID 18182679 DOI: 10.1177/1076029607312278  0.373
2008 Adiguzel C, Hoppensteadt D, Cunanan J, Bick R, Walenga J, Fareed J. Prevalence of heparin induced thrombocytopenia antibodies in cancer patients treated with a low molecular weight heparin Journal of Clinical Oncology. 26: 20601-20601. DOI: 10.1200/Jco.2008.26.15_Suppl.20601  0.328
2008 Hoppensteadt D, Jeske W, Walenga J, Fareed J. AVE5026: A new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis Journal of Clinical Oncology. 26: 14653-14653. DOI: 10.1200/Jco.2008.26.15_Suppl.14653  0.316
2008 Bansal V, Fareed D, Hoppensteadt D, Cunanan J, Fareed J. Increased Procalcitonin Levels in End Stage Renal Disease and Chronic Kidney Disease as An Indicator of Inflammatory Activation Blood. 112: 5472-5472. DOI: 10.1182/Blood.V112.11.5472.5472  0.326
2008 Iqbal O, Adiguzel C, Fareed J, Hoppensteadt D, Litinas E, Zhu H, Halaris A. Selective Serotonin Reuptake Inhibitors Influence Agonist-Induced Platelet Aggregation. Preliminary Results from Comorbidity of Depression and Cardiovascular Disease Study Blood. 112: 4556-4556. DOI: 10.1182/Blood.V112.11.4556.4556  0.363
2008 Fareed J, Iqbal O, Hoppensteadt D, Adiguzel C, Iacobelli M, Walenga JM. Defibrotide Augments the Anticoagulant Actions of Heparin and Low Molecular Weight Heparins Blood. 112: 4086-4086. DOI: 10.1182/Blood.V112.11.4086.4086  0.38
2008 Adiguzel C, Bansal V, Cunanan J, Litinas E, Hoppensteadt D, Fareed J. Increased Levels of Anaphylatoxin (C5a) and Bradykinin in End-Stage Renal Disease Patients on Maintenance Hemodialysis. Potential Relevance to Heparin Mediated Hemodynamic Responses Blood. 112: 4079-4079. DOI: 10.1182/Blood.V112.11.4079.4079  0.307
2008 Adiguzel C, Bansal V, Cunanan J, Litinas E, Hoppensteadt D, Fareed J. Fibrinokinetic Deficit in Chronic Kidney Disease and End Stage Renal Disease Patients Contributes to the Hemostatic Abnormalities Blood. 112: 4078-4078. DOI: 10.1182/Blood.V112.11.4078.4078  0.308
2008 Fareed J, Hoppensteadt D, Jeske W, Adiguzel C, Iqbal O, Walenga JM. Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions Blood. 112: 4048-4048. DOI: 10.1182/Blood.V112.11.4048.4048  0.386
2008 Hoppensteadt D, Jeske W, Walenga JM, Fareed J. AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis Blood. 112: 4046-4046. DOI: 10.1182/Blood.V112.11.4046.4046  0.32
2008 Bansal V, Cunanan J, Adiguzel C, Litinas E, Nelson K, Fareed J. A Higher Prevalence of HIT Antibodies in Patients May Be Due to Contaminated Heparin Blood. 112: 3022-3022. DOI: 10.1182/Blood.V112.11.3022.3022  0.41
2008 Kuziej J, Litinas E, Hoppensteadt D, Liu D, Walenga JM, Fareed J, Jeske W. In Vivo Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by a Novel Salicylamide Derivative. Blood. 112: 1825-1825. DOI: 10.1182/Blood.V112.11.1825.1825  0.368
2008 Kannan M, Ahmad F, Yadav BK, Kumar R, Fareed J, Saxena R. Glanzmann’s Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE) Blood. 112: 1236-1236. DOI: 10.1182/Blood.V112.11.1236.1236  0.322
2008 Fareed J, Walenga J, Jeske W, Hoppensteadt D, Prechel M, Iqbal O, Adiguzel C, Clark M, Litinas E, Cunanan J, Linhardt R, Harenberg J. Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Seminars in Thrombosis and Hemostasis. 34: 119-127. DOI: 10.1055/S-0028-1086092  0.369
2008 Adiguzel C, Iqbal O, Cunanan J, Jeske W, Hoppensteadt D, Walenga JM, Fareed J. Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Seminars in Thrombosis and Hemostasis. 34: 108-118. DOI: 10.1055/S-0028-1086091  0.403
2008 Hoppensteadt DA, Jeske W, Walenga JM, Bick RL, Fareed J. The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors: Experimental and Clinical Observations Seminars in Thrombosis and Hemostasis. 34: 97-102. DOI: 10.1055/S-0028-1086089  0.388
2007 Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, Hoppensteadt DA, Carbon F, Cavusoglu E, Varon D, Viles-Gonzalez JF, Badimon JJ, Marmur JD. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. The American Journal of Cardiology. 100: 417-24. PMID 17659921 DOI: 10.1016/J.Amjcard.2007.02.106  0.372
2007 Demir M, Duran E, Yigitbasi O, Vural O, Kurum T, Yuksel M, Turgut B, Walenga JM, Fareed J. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Clinical and Applied Thrombosis-Hemostasis. 13: 279-284. PMID 17636189 DOI: 10.1177/1076029607299987  0.352
2007 Fareed J, Walenga JM. Why differentiate low molecular weight heparins for venous thromboembolism Thrombosis Journal. 5: 8-8. PMID 17578577 DOI: 10.1186/1477-9560-5-8  0.379
2007 Fareed J, Bick RL, Kessler C, Messmore HL, Rao G, Sasahara A, Haas S. Potential thrombogenic complications with the use of recombinant activated factor VII in combat trauma. Clinical and Applied Thrombosis-Hemostasis. 13: 121-123. PMID 17456619 DOI: 10.1177/1076029606298733  0.3
2007 Maddineni J, Hoppensteadt DA, Cornelli U, Manoni M, Fareed J. Relative Neutralization of the Biological Actions of Sulfaminoheparosans (K5 Derivatives) and Heparins by Protamine Sulfate Clinical and Applied Thrombosis-Hemostasis. 13: 52-64. PMID 17164496 DOI: 10.1177/1076029606296403  0.357
2007 Iqbal O, Adiguzel C, Hoppensteadt D, Cunannan J, Fareed J. Factor Xa Inhibitors Can Be Differentiated in Xa, IIa and Microparticle Generation and Other Whole Blood Based Assays. Blood. 110: 931-931. DOI: 10.1182/Blood.V110.11.931.931  0.372
2007 Adiguzel C, Iqbal O, Sammikannu M, Cunanan J, Jeske W, Hoppensteadt D, Fareed J. Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays. Blood. 110: 4007-4007. DOI: 10.1182/Blood.V110.11.4007.4007  0.39
2007 Jeske WP, Brubaker A, Hoppensteadt D, Walenga JM, Ma Q, Fareed J. Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin. Blood. 110: 3999-3999. DOI: 10.1182/Blood.V110.11.3999.3999  0.353
2007 Adiguzel C, Iqbal O, Fareed D, Hoppensteadt D, Jeske W, Simmikannu M, Fareed J. Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications. Blood. 110: 3898-3898. DOI: 10.1182/Blood.V110.11.3898.3898  0.365
2007 Hoppensteadt D, Fareed J, Klein A, Jasper S, Apperson-Hansen C, Lieber E, Katz W, Malouf J, Stoddard M. Suppression of Markers of Thrombin Generation and Inflammation in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for TEE-Guided Cardioversion of Atrial Fibrillation. Blood. 110: 3621-3621. DOI: 10.1182/Blood.V110.11.3621.3621  0.371
2007 Fareed J, Prechel M, Kujawski M, Zhu H, Walenga J, Hoppensteadt D, Cunanan J, Saxena R. Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications. Blood. 110: 3206-3206. DOI: 10.1182/Blood.V110.11.3206.3206  0.381
2007 Kujawski MR, Prechel M, Zhu H, Walenga J, Hoppensteadt D, Cunanan J, Adiguzel C, Fareed J. A Unique Biomarker Is Associated with the Prevalence of Functional Heparin Induced Thrombocytopenia (HIT) Associated Antibodies: Results from Proteomic (ProteinChip Array) Profiling of ELISA Positive HIT Plasma Samples. Blood. 110: 3205-3205. DOI: 10.1182/Blood.V110.11.3205.3205  0.344
2007 Cunanan J, Kujawski M, Zhu H, Prechel M, Walenga J, Hoppensteadt D, Fareed J. Functional Microparticles Are up Regulated in Patients with Anti-Heparin/Platelet Factor 4 Antibodies: A Potential Mechanism of Thrombogenesis in the Heparin-Induced Thrombocytopenia Syndrome. Blood. 110: 2105-2105. DOI: 10.1182/Blood.V110.11.2105.2105  0.381
2007 Echart C, Repice C, Ferro L, Anderson K, Richardson P, Falanga A, Fareed J, Iacobelli M. Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity. Blood. 110: 1992-1992. DOI: 10.1182/Blood.V110.11.1992.1992  0.349
2007 Jeske W, Brubaker A, Liu D, Young T, Hoppensteadt D, Iqbal O, Fareed J, Walenga JM, Bakhos M. In Vitro Characterization of the Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives. Blood. 110: 1869-1869. DOI: 10.1182/Blood.V110.11.1869.1869  0.411
2007 Fabbrini N, Hoppensteadt D, Messmore H, Bick R, Adiguzel C, Fareed J. Upregulation of Microparticles and CD40 Ligand in Antiphospholipid Syndrome: Potential Implication in Inflammatory Responses and Thrombosis. Blood. 110: 1740-1740. DOI: 10.1182/Blood.V110.11.1740.1740  0.303
2007 McGeehan E, Azarafrooz F, Cera L, Buesing R, Hoppensteadt D, Fareed J. Relative Anticoagulant And Antithrombotic Effects Of Heparin And Low Molecular Weight Heparins In Human And Feline Blood Plasma. Potential Therapeutic Implications Journal of Thrombosis and Haemostasis. 5. DOI: 10.1111/J.1538-7836.2007.Tb03178.X  0.356
2007 Fareed D, Hoppensteadt D, Walenga JM, Jeske WP, Bick R, Fareed J. Recombinant Thrombomodulin Does Not Cross React With Anti-Heparin Platelet Factor 4 Antibodies. Potential Implication For Anticoagulation Of Heparin-Induced Thrombocytopenia Patients Journal of Thrombosis and Haemostasis. 5. DOI: 10.1111/J.1538-7836.2007.Tb02083.X  0.373
2007 Wahi R, Hoppensteadt D, Tobu M, Iqbal O, Walenga JM, Demir M, Fareed D, Fareed J. Comparative Study On The Anticoagulant Effects Of Unfractionated And Low Molecular Weight Heparins, Lower Low Molecular Weight Heparins And Pentasaccahride As Measured By Whole Blood Act, Anti-Xa And A Newly Developed Prothrombinase Induced Clotting Time Journal of Thrombosis and Haemostasis. 5. DOI: 10.1111/J.1538-7836.2007.Tb00781.X  0.348
2007 Erez O, Romero R, Hoppensteadt D, Fareed J, Chaiworapongsa T, Kusanovic JP, Mazaki-Tovi S, Gotsch F, Than NG, Vaisbuch E, Kim CJ, Espinoza J, Mittal P, Nhan-Chang C, Hamill N, et al. 123: Is premature labor a state of platelet activation? American Journal of Obstetrics and Gynecology. 197. DOI: 10.1016/J.Ajog.2007.10.134  0.315
2006 Fareed J, Jeske WP, Hoppensteadt DA, Walenga JM. Update on the clinical applications of argatroban. Future Cardiology. 2: 403-414. PMID 19804176 DOI: 10.2217/14796678.2.4.403  0.343
2006 Maddineni J, Jeske WP, Baltasar F, Cornelli U, Manoni M, Hoppensteadt DA, Fareed J. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis. Clinical and Applied Thrombosis-Hemostasis. 12: 311-317. PMID 16959684 DOI: 10.1177/1076029606291426  0.417
2006 Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 12: 267-76. PMID 16959680 DOI: 10.1177/1076029606291434  0.333
2006 Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, Cornelli U, Lee J, Linhardt R, Hanin I, Fareed J. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thrombosis Research. 119: 653-61. PMID 16824584 DOI: 10.1016/J.Thromres.2006.05.007  0.344
2006 Jeske WP, Walenga JM, Ackerman PD, Hoppensteadt DA, Vandenberg C, Bick RL, Fareed J. Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin. Blood. 108: 908-908. DOI: 10.1182/Blood.V108.11.908.908  0.373
2006 Fareed J, Hoppensteadt D, Bansal V, Walenga J, Lale A, Bick R. Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Receptors. Experimental and Clinical Observations. Blood. 108: 4132-4132. DOI: 10.1182/Blood.V108.11.4132.4132  0.359
2006 Hoppensteadt DA, Bansal V, Cunanan J, Patel K, Wahi R, Fareed J. Prevalence of Cross Reactive Epitopes to Bovine Factor Va Light Chain Fragments in Normal and Patients Plasma. Blood. 108: 4022-4022. DOI: 10.1182/Blood.V108.11.4022.4022  0.352
2006 Kujawski M, Cunanan J, Hoppensteadt DA, Bick RL, Fareed J. Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications. Blood. 108: 4016-4016. DOI: 10.1182/Blood.V108.11.4016.4016  0.316
2006 Lale A, Lale S, Bick R, Fareed J. Dengue Fever and Thrombocytopenia: A Deadly Duo. Blood. 108: 3978-3978. DOI: 10.1182/Blood.V108.11.3978.3978  0.358
2006 Cunanan J, Hoppensteadt D, Bansal V, Fareed J. Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm. Blood. 108: 3838-3838. DOI: 10.1182/Blood.V108.11.3838.3838  0.325
2006 Fareed J, Sonevytsky A, Iqbal O, Jeske WP, Iacobelli M, Hoppensteadt D. Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications. Blood. 108: 1626-1626. DOI: 10.1182/Blood.V108.11.1626.1626  0.376
2006 Hoppensteadt D, Fareed D, Iqbal O, Lale A, Fareed J. Nitric Oxide and Asymmetric Dimethlyarginine Levels in Malignancy Associated Thrombosis and Their Modulaiton by Anticoagulants. Blood. 108: 1477-1477. DOI: 10.1182/Blood.V108.11.1477.1477  0.328
2006 Fareed J, Hoppensteadt DA, Iacobelli M, Walenga JM. Defibrotide Does Not Cross-React with HIT Antibodies. Implications in the Management of HIT. Blood. 108: 1054-1054. DOI: 10.1182/Blood.V108.11.1054.1054  0.425
2006 Sonevytsky A, Jeske W, Hoppensteadt D, Baltasar F, Florian M, Fareed J. Differences in the native and heparinase I digestion profiles of a generic enoxaparin: Pharmacologic implications The Faseb Journal. 20. DOI: 10.1096/Fasebj.20.5.Lb105  0.306
2006 Erez O, Espinoza J, Chaiworapongsa T, Gotsch F, Kusanovic JP, Than NG, Mazaki-Tovi S, Papp Z, Yoon BH, Hoppensteadt D, Fareed J, Hassan S, Romero R. Tissue factor and tissue pathway inhibitor: A link between a hemostatic disorder and preterm PROM? American Journal of Obstetrics and Gynecology. 195: S51. DOI: 10.1016/J.Ajog.2006.10.147  0.308
2005 Haas S, Wolf H, Kakkar AK, Fareed J, Encke A. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thrombosis and Haemostasis. 94: 814-9. PMID 16270636 DOI: 10.1160/Th02-10-0189  0.33
2005 Kannan M, Ahmad S, Ahmad F, Kale S, Hoppensteadt DA, Fareed J, Saxena R. Functional characterization of antibodies against heparin-platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers. Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 16: 487-90. PMID 16175007 DOI: 10.1097/01.Mbc.0000178829.31902.0A  0.393
2005 Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents Expert Opinion On Investigational Drugs. 14: 847-858. PMID 16022574 DOI: 10.1517/13543784.14.7.847  0.336
2005 Kemkes-Matthes B, Walenga JM, Harenberg J, Fareed J. Argatroban treatment for patients with intolerance to heparin and hirudin. Clinical and Applied Thrombosis-Hemostasis. 11: 99-103. PMID 15678280 DOI: 10.1177/107602960501100113  0.335
2005 Tobu M, Ma Q, Iqbal O, Schultz C, Jeske W, Hoppensteadt DA, Fareed J. Comparative tissue factor pathway inhibitor release potential of heparins. Clinical and Applied Thrombosis-Hemostasis. 11: 37-47. PMID 15678271 DOI: 10.1177/107602960501100104  0.349
2005 Iqbal O, Tobu M, Aziz S, Gerdisch M, Valle MD, Demir M, Hoppensteadt DA, Ahmad S, Walenga JM, Fareed J. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Journal of Cardiac Surgery. 20: 42-51. PMID 15673409 DOI: 10.1111/J.0886-0440.2005.200316.X  0.309
2005 Fareed J, Leong W, Hoppensteadt DA, Jeske WP, Walenga J, Bick RL. Development of generic low molecular weight heparins: a perspective. Hematology-Oncology Clinics of North America. 19: 53-68. PMID 15639108 DOI: 10.1016/J.Hoc.2004.09.005  0.311
2005 Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematology/Oncology Clinics of North America. 19: 1-51, v. PMID 15639107 DOI: 10.1016/J.Hoc.2004.09.003  0.316
2005 Kannan M, Ahmad F, Ahmad S, Kale S, Fareed J, Saxena R. Heparin-PF4 Antibodies in Heparin Induced Thrombocytopenia: Its Relationship with FcgRIIa Polymorphism American Journal of Immunology. 1: 55-59. DOI: 10.3844/Ajisp.2005.55.59  0.361
2005 Fareed J, Hoppensteadt D, Cort S, Iqbal O, Bacher P, Fareed D, Tobu M, Deitcher S. Enoxaparin (E) and warfarin (W) differentially regulate tissue factor (TF), tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI) in cancer patients with thrombosis Journal of Clinical Oncology. 23: 2057-2057. DOI: 10.1200/Jco.2005.23.16_Suppl.2057  0.323
2005 Jeske WP, Cunanan J, Hoppensteadt D, Walenga JM, Iqbal O, Florian-Kujawski M, Fareed J. Discordance between the 1st and 2nd Low Molecular Weight Heparin Standards. Implications for Dosing. Blood. 106: 4158-4158. DOI: 10.1182/Blood.V106.11.4158.4158  0.336
2005 Hoppensteadt D, Tobu M, Wahi R, Iqbal O, Walenga JM, Demir M, Baltasar F, Fareed J. Comparative Study on the Anticoagulant Effects of Low Molecular Weight Heparins as Measured by Whole Blood Act, Anti-Xa and a Newly Developed Prothrombinase Induced Clotting Time (PiCT) Assay. Blood. 106: 4148-4148. DOI: 10.1182/Blood.V106.11.4148.4148  0.384
2005 Hoppensteadt D, Jeske W, Fareed D, Baltasar F, Walenga JM, Tobu M, Demir M, Iqbal O, Wahi R, Fareed J. Clinical and Laboratory Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003-01/608) in the Anti-Xa, Anti-LIA Heptest and Prothrombinase Induced Clotting (PiCT) Tests. Blood. 106: 4147-4147. DOI: 10.1182/Blood.V106.11.4147.4147  0.357
2005 Fareed J, Hoppensteadt D, Cunanan J, Patel C, Maddineni J, Baltasar F, Fareed D, Demir M, Tobu M, Iqbal O, Bansal V, Greenfield R. Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease. Blood. 106: 4116-4116. DOI: 10.1182/Blood.V106.11.4116.4116  0.325
2005 Florian-Kujawski MR, Hoppensteadt D, Cunanan J, Wilmer M, Fareed J. Relative Inhibition of Thrombin Activatable Fibrinolytic Inhibitor by Newly Developed Thrombin Inhibitors: Impact on Bleeding and Antithrombotic Actions. Blood. 106: 4051-4051. DOI: 10.1182/Blood.V106.11.4051.4051  0.352
2005 Hoppensteadt D, Cunanan J, Walenga JM, Ero MP, Jeske WP, Bick R, Fareed J. Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia. Blood. 106: 3970-3970. DOI: 10.1182/Blood.V106.11.3970.3970  0.4
2005 Hoppensteadt D, Tobu M, Fareed D, Iqbal O, Baltasar F, Patel C, Bansal V, Demir M, Fareed J. Frequency of Anti-Erythropoietin Antibodies in Patients with End Stage Renal Disease Treated with Recombinant Erythropoietin. Blood. 106: 3554-3554. DOI: 10.1182/Blood.V106.11.3554.3554  0.323
2005 Fareed J, Hoppensteadt D, Haque W, Diakur J, Jeske W, Florian-Kujawski M, Maddineni J, Baltasar F, Neville B, Walenga JM. Biochemical and Pharmacologic Profiling of a Novel Dual Acting Antithrombin Agent with Antiprotease and Antiplatelet Actions. Hematologic Implications. Blood. 106: 1876-1876. DOI: 10.1182/Blood.V106.11.1876.1876  0.383
2004 Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL. Generic low-molecular-weight heparins: some practical considerations. Seminars in Thrombosis and Hemostasis. 30: 703-13. PMID 15630677 DOI: 10.1055/S-2004-861513  0.361
2004 Fareed D, Iqbal O, Tobu M, Hoppensteadt DA, Fareed J. Blood Levels of Nitric Oxide, C-Reactive Protein, and Tumor Necrosis Factor-α Are Upregulated in Patients with Malignancy-Associated Hypercoagulable State: Pathophysiologic Implications Clinical and Applied Thrombosis-Hemostasis. 10: 357-364. PMID 15497022 DOI: 10.1177/107602960401000408  0.302
2004 Tobu M, Iqbal O, Hoppensteadt D, Neville B, Messmore HL, Fareed J. Anti-Xa and Anti-IIa Drugs Alter International Normalized Ratio Measurements: Potential Problems in the Monitoring of Oral Anticoagulants Clinical and Applied Thrombosis-Hemostasis. 10: 301-309. PMID 15497016 DOI: 10.1177/107602960401000402  0.301
2004 Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fareed J. Erythropoietin-Induced Thrombosis as a Result of Increased Inflammation and Thrombin Activatable Fibrinolytic Inhibitor Clinical and Applied Thrombosis-Hemostasis. 10: 225-232. PMID 15247979 DOI: 10.1177/107602960401000304  0.32
2004 Fareed J, Jeske WP. Small-molecule direct antithrombins: argatroban Best Practice & Research Clinical Haematology. 17: 127-138. PMID 15171962 DOI: 10.1016/J.Beha.2004.03.008  0.411
2004 Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, Bick RL. Differentiation of low-molecular-weight heparins: Impact on the future of the management of thrombosis Seminars in Thrombosis and Hemostasis. 30: 89-104. PMID 15085470 DOI: 10.1055/S-2004-823007  0.391
2004 Messmore HL, Wehrmacher WH, Coyne E, Fareed J. Heparin to pentasaccharide and beyond: the end is not in sight. Seminars in Thrombosis and Hemostasis. 30: 81-88. PMID 15085469 DOI: 10.1055/S-2004-823006  0.353
2004 Hoppensteadt DA, Willows L, Leitz H, Nicolaides A, Fareed J. Laboratory analysis of blood samples from patients treated with tinzaparin. Seminars in Thrombosis and Hemostasis. 30: 49-55. PMID 15085466 DOI: 10.1055/S-2004-823003  0.364
2004 Jeske W, Fareed J. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. Seminars in Thrombosis and Hemostasis. 30: 41-47. PMID 15085465 DOI: 10.1055/S-2004-823002  0.361
2004 Messmore HL, Coyne E, Wehrmacher WH, Demir AM, Fareed J. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. Current Pharmaceutical Design. 10: 1001-1010. PMID 15078129 DOI: 10.2174/1381612043452802  0.356
2004 Fareed J, Hoppensteadt D, Schultz C, Ma Q, Kujawski MF, Messmore H. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Current Pharmaceutical Design. 10: 983-999. PMID 15078128 DOI: 10.2174/1381612043452811  0.366
2004 Ahmad S, Untch B, Haas S, Hoppensteadt DA, Misselwitz F, Messmore HL, Walenga JM, Fareed J. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Molecular and Cellular Biochemistry. 258: 163-170. PMID 15030181 DOI: 10.1023/B:Mcbi.0000012852.60500.30  0.368
2004 Kannan M, Ahmed R, Kale S, Ahmad S, Fareed J, Saxena R. Laboratory diagnosis of heparin-induced thrombocytopenia in Asian Indians as investigated with functional and immunologic methods. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 10: 51-4. PMID 14979405 DOI: 10.1177/107602960401000108  0.372
2004 Maddineni J, Ma Q, Hoppensteadt DA, Demir M, Manoni M, Cornelli U, Fareed J. Molecular and Pharmacologic Profile of Tinzaparin and A Comparable Low-Molecular-Weight Bacterial Sulfaminoheparosan: Clinical and Applied Thrombosis-Hemostasis. 10: 27-37. PMID 14979402 DOI: 10.1177/107602960401000105  0.325
2004 Tobu M, Hoppensteadt DA, Cunanan J, Iqbal O, Demir MA, Fareed J, Deitcher S. Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation Journal of Clinical Oncology. 22: 6152-6152. DOI: 10.1200/Jco.2004.22.90140.6152  0.305
2004 Iqbal O, Hoppensteadt D, Fareed D, Fareed J. Synthetic Anti-Xa Drugs Can Be Used for Parenteral Anticoagulation but Not Fondaparinux. Blood. 104: 4088-4088. DOI: 10.1182/Blood.V104.11.4088.4088  0.372
2004 Cornelli U, Maddineni J, Vana L, Hoppensteadt D, Florian-Kujawski M, Fareed J. Development of Non-Anticoagulant Derivatives of Biotechnology Derived Sulfaminoheparosan Derivatives to Investigate the Non-Anticoagulant Effects of these Agents. Blood. 104: 4069-4069. DOI: 10.1182/Blood.V104.11.4069.4069  0.371
2004 Fareed J, Tobu M, Hoppensteadt DA, Cunanan J, Iqbal O, Demir M, Deitcher S. Hyperhomocysteinemia in Cancer Patients with Thrombosis Is Independent of Methylene Tetrahydrofolate Reductase Gene Mutation. Blood. 104: 4055-4055. DOI: 10.1182/Blood.V104.11.4055.4055  0.32
2004 Florian-Kujawski M, Hoppensteadt D, Wilmer M, Fareed J. Thrombin Activatable Fibrinolytic Inhibitor Modulation in Heparin Supplemented Plasma: Clinical Considerations. Blood. 104: 3998-3998. DOI: 10.1182/Blood.V104.11.3998.3998  0.357
2004 Hoppensteadt DA, Cunanan J, Walenga JM, Fareed J, Wilmer M, Janssen M. Clinical evaluation of a new functional, plasma-based assay for the detection of Factor V Leiden - the pefalkit (R) APC-R Factor v Leiden assay. Blood. 104: 3997-3997. DOI: 10.1182/Blood.V104.11.3997.3997  0.31
2004 Florian-Kujawski M, Greene T, Hoppensteadt D, Fareed J. Tissue Factor Mediated Activation of Prothrombin Complex Concentrates and its Inhibition by Antithrombin Drugs. Blood. 104: 2986-2986. DOI: 10.1182/Blood.V104.11.2986.2986  0.346
2004 Jeske WP, Neville B, Ma Q, Hoppensteadt DA, Fareed J. Effect of 1,6-Anhydro Bicyclic Ring Structure on the Pharmacokinetic and Pharmacodynamic Behavior of Low Molecular Weight Heparin. Blood. 104: 1868-1868. DOI: 10.1182/Blood.V104.11.1868.1868  0.392
2004 Hoppensteadt DA, Cunanan J, Walenga JM, Fareed J. Development of Prothrombinase Induced Clotting Time (Pefakit ®, PiCT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs. Blood. 104: 1858-1858. DOI: 10.1182/Blood.V104.11.1858.1858  0.365
2004 Walenga JM, Fareed D, Schultz C, Neville B, Hoppensteadt D, Iqbal O, Fareed J. Argatroban, Not Lepirudin or Bivalirudin, Treatment Results in the Generation of Nitric Oxide during Parenteral Administration. Blood. 104: 1849-1849. DOI: 10.1182/Blood.V104.11.1849.1849  0.322
2003 Tobu M, Iqbal O, Messmore HL, Ma Q, Hoppensteadt DA, Fareed J. Influence of different anticoagulant agents on fibrinopeptide a generation. Clinical and Applied Thrombosis-Hemostasis. 9: 273-292. PMID 14653437 DOI: 10.1177/107602960300900403  0.356
2003 Stief TW, Bünder R, Richter A, Maisch B, Renz H, Fareed J. In vitro Simulation of Therapeutic Plasmatic Fibrinolysis Clinical and Applied Thrombosis-Hemostasis. 9: 211-220. PMID 14507109 DOI: 10.1177/107602960300900305  0.301
2003 Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Clinical Pharmacokinectics. 42: 1043-1057. PMID 12959635 DOI: 10.2165/00003088-200342120-00003  0.391
2003 Fareed J, Hoppensteadt DA, Bick RL. Management of Thrombotic and Cardiovascular Disorders in the New Millenium Clinical and Applied Thrombosis-Hemostasis. 9: 101-108. PMID 12812377 DOI: 10.1177/107602960300900202  0.332
2003 Ahmad S, Bacher HP, Lassen MR, Hoppensteadt DA, Leitz H, Misselwitz F, Walenga JM, Fareed J. Investigations of the Immunoglobulin Subtype Transformation of Anti-Heparin-Platelet Factor 4 Antibodies During Treatment With a Low-Molecular-Weight Heparin (Clivarin) in Orthopedic Patients Archives of Pathology & Laboratory Medicine. 127: 584-588. PMID 12708902 DOI: 10.1043/0003-9985(2003)127<0584:Iotist>2.0.Co;2  0.405
2003 Tobu M, Iqbal O, Ma Q, Schultz C, Jeske W, Hoppensteadt D, Lewis B, Fareed D, Fareed J. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Clinical and Applied Thrombosis-Hemostasis. 9: 1-17. PMID 12643318 DOI: 10.1177/107602960300900101  0.304
2003 Hoppensteadt D, Walenga JM, Fareed J, Bick RL. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematology-Oncology Clinics of North America. 17: 313-341. PMID 12627673 DOI: 10.1016/S0889-8588(02)00091-6  0.358
2003 Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. Journal of the American College of Cardiology. 41: 394-402. PMID 12575965 DOI: 10.1016/S0735-1097(02)02762-6  0.384
2003 Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, Bick R. Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology Seminars in Cardiothoracic and Vascular Anesthesia. 7: 357-377. DOI: 10.1177/108925320300700402  0.355
2003 Kumar P, Deddish RB, Walenga JM, Hoppensteadt DA, Prechel MM, Drenth A, Messmore HL, Fareed J. Heparin-induced anti-platelet antibodies in very low birth-weight infants Journal of Thrombosis and Haemostasis. 1. DOI: 10.1111/J.1538-7836.2003.Tb05690.X  0.316
2003 Hoppensteadt D, Mayuga M, Lietz H, Florian-Kujawski M, Ahmad S, Frapaise X, Bacher P, Breddin HK, Reid U, Fareed J. Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis Journal of Thrombosis and Haemostasis. 1. DOI: 10.1111/J.1538-7836.2003.Tb05445.X  0.355
2003 Ahmad S, Haas S, Bacher P, Misselwitz F, Reid U, Hoppensteadt DA, Fareed J. Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications Journal of Thrombosis and Haemostasis. 1. DOI: 10.1111/J.1538-7836.2003.Tb05434.X  0.345
2003 Florian-Kujawski M, Hoppensteadt DA, Tobu M, Kereiakes DJ, Lewis B, Leya F, Fareed J. Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins Journal of Thrombosis and Haemostasis. 1. DOI: 10.1111/J.1538-7836.2003.Tb04435.X  0.314
2002 Fareed J, Hoppensteadt D, Iqbal O, Tobu M, Lewis BE. Practical issues in the development of argatroban: A perspective Pathophysiology of Haemostasis and Thrombosis. 32: 56-65. PMID 12811013 DOI: 10.1159/000069110  0.354
2002 Ahmad S, Haas S, Hoppensteadt DA, Lietz H, Reid U, Bender N, Messmore HL, Misselwitz F, Bacher P, Gaikwad BS, Jeske WP, Walenga JM, Fareed J. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies Thrombosis Research. 108: 49-55. PMID 12586132 DOI: 10.1016/S0049-3848(02)00397-3  0.387
2002 Tobu M, Iqbal O, Hoppensteadt DA, Shultz C, Jeske W, Fareed J. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests. Clinical and Applied Thrombosis-Hemostasis. 8: 325-336. PMID 12516682 DOI: 10.1177/107602960200800404  0.322
2002 Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. Monitoring of argatroban in ARG310 study: Potential recommendations for its use in interventional cardiology Clinical and Applied Thrombosis/Hemostasis. 8: 217-224. PMID 12361198 DOI: 10.1177/107602960200800304  0.329
2002 Untch B, Ahmad S, Messmore HL, Schultz CL, Ma Q, Hoppensteadt DA, Walenga JM, Fareed J. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. Thrombosis Research. 106: 149-156. PMID 12182915 DOI: 10.1016/S0049-3848(02)00081-6  0.394
2002 Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I, Fareed J. The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thrombosis Research. 105: 447-53. PMID 12062547 DOI: 10.1016/S0049-3848(02)00050-6  0.304
2002 Ma Q, Dudas B, Daud A, Iqbal O, Hoppensteadt D, Jeske W, Cornelli U, Lee J, Lorens S, Mervis R, Hanin I, Capila I, Linhardt R, Fareed J. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. Thrombosis Research. 105: 303-9. PMID 12031824 DOI: 10.1016/S0049-3848(01)00413-3  0.301
2002 Untch B, Ahmad S, Jeske WP, Messmore HL, Hoppensteadt DA, Walenga JM, Lietz H, Fareed J. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thrombosis Research. 105: 117-123. PMID 11958801 DOI: 10.1016/S0049-3848(02)00004-X  0.378
2002 Kakkar VV, Hoppenstead DA, Fareed J, Kadziola Z, Scully M, Nakov R, Breddin HK. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis Blood. 99: 1965-1970. PMID 11877267 DOI: 10.1182/Blood.V99.6.1965  0.329
2002 Kaiser P, Harenberg J, Walenga JM, Huhle G, Giese C, Prechel M, Hoppensteadt D, Fareed J. Effects of a heparin-binding protein on blood coagulation and platelet function. Seminars in Thrombosis and Hemostasis. 27: 495-502. PMID 11668419 DOI: 10.1055/S-2001-17960  0.397
2001 Iqbal O, Aziz S, Hoppensteadt DA, Ahmad S, Walenga JM, Bakhos M, Fareed J. Emerging anticoagulant and thrombolytic drugs. Expert Opinion On Emerging Drugs. 6: 111-135. PMID 15989500 DOI: 10.1517/14728214.6.1.111  0.361
2001 Kaiser B, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion On Investigational Drugs. 10: 1925-1935. PMID 11772296 DOI: 10.1517/13543784.10.11.1925  0.371
2001 Stief TW, Feek U, Ramaswamy A, Kretschmer V, Renz H, Fareed J. Singlet Oxygen (1O2) Disrupts Platelet Aggregates Thrombosis Research. 104: 361-370. PMID 11738079 DOI: 10.1016/S0049-3848(01)00367-X  0.331
2001 Kanabrocki EL, George M, Hermida RC, Messmore HL, Ryan MD, Ayala DE, Hoppensteadt DA, Fareed J, Bremner FW, Third JL, Shirazi P, Nemchausky BA. Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 7: 339-45. PMID 11697721 DOI: 10.1177/107602960100700417  0.303
2001 Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, Fareed J. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest. 120: 1226-30. PMID 11591565 DOI: 10.1378/Chest.120.4.1226  0.305
2001 Hoppensteadt DA, Fareed J, Raake P, Raake W. Endogenous Release of Tissue Factor Pathway Inhibitor by Topical Application of an Ointment Containing Mucopolysaccharide Polysulfate to Nonhuman Primates Thrombosis Research. 103: 157-163. PMID 11457474 DOI: 10.1016/S0049-3848(01)00280-8  0.34
2001 Cella G, Sbarai A, Mazzaro G, Motta G, Carraro P, Andreozzi GM, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 7: 225-8. PMID 11441984 DOI: 10.1177/107602960100700308  0.366
2001 Stief TW, Jeske WP, Walenga J, Schultz C, Kretschmer V, Fareed J. Singlet oxygen inhibits agonist-induced P-selectin expression and formation of platelet aggregates. Clinical and Applied Thrombosis-Hemostasis. 7: 219-224. PMID 11441983 DOI: 10.1177/107602960100700307  0.316
2001 Ahmad S, Jeske WP, Ma Q, Walenga JM, Fareed J. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Thrombosis Research. 102: 143-151. PMID 11323025 DOI: 10.1016/S0049-3848(01)00225-0  0.41
2001 Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 103: 1838-43. PMID 11294800 DOI: 10.1161/01.Cir.103.14.1838  0.318
2001 Piccolo P, Iqbal O, Demir M, Ma Q, Gerbutavicius R, Fareed J. Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture. Clinical and Applied Thrombosis-Hemostasis. 7: 149-152. PMID 11292193 DOI: 10.1177/107602960100700212  0.336
2001 Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, Linhardt RJ, Fareed J. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 7: 131-40. PMID 11292191 DOI: 10.1177/107602960100700210  0.373
2001 Hakki SI, Fareed J, Hoppensteadt DA, Abdullah H, Camblin J, Nasseri AF, Hamadeh O, Wright T. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 7: 65-71. PMID 11190908 DOI: 10.1177/107602960100700113  0.335
2001 Daud AN, Ahsan A, Iqbal O, Walenga JM, Silver PJ, Ahmad S, Fareed J. Synthetic Heparin Pentasaccharide Depolymerization by Heparinase 1: Molecular and Biological Implications Clinical and Applied Thrombosis-Hemostasis. 7: 58-64. PMID 11190907 DOI: 10.1177/107602960100700112  0.366
2001 Demir M, Iqbal O, Dietrich CP, Hoppensteadt DA, Ahmad S, Daud AN, Fareed J. Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I. Clinical and Applied Thrombosis-Hemostasis. 7: 44-52. PMID 11190904 DOI: 10.1177/107602960100700110  0.371
2001 Demir M, Iqbal O, Untch B, Hoppensteadt DA, Gaikwad BS, Fareed J. Ecarin Clotting Time is Sensitive to Heparinoids: Comparison of Two Different Techniques Clinical and Applied Thrombosis-Hemostasis. 7: 38-43. PMID 11190903 DOI: 10.1177/107602960100700109  0.344
2001 Santillan MKO, Herring J, Hoppensteadt DA, Jeske W, Herbert J, Fareed J. The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys. Clinical and Applied Thrombosis-Hemostasis. 7: 10-15. PMID 11190897 DOI: 10.1177/107602960100700103  0.341
2001 Thiel DHV, George M, Fareed J. Low Levels of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Chronic Liver Disease Thrombosis and Haemostasis. 85: 667-670. DOI: 10.1055/S-0037-1615651  0.32
2000 Scazziota A, Altman R, Rouvier J, Gonzalez C, Ahmed Z, Jeske WP, Walenga JM, Fareed J. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression. Thrombosis Research. 100: 479-488. PMID 11152927 DOI: 10.1016/S0049-3848(00)00361-3  0.331
2000 Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a review. Archives of Pathology & Laboratory Medicine. 124: 1657-1666. PMID 11079020 DOI: 10.1043/0003-9985(2000)124<1657:Pohit>2.0.Co;2  0.405
2000 Ahmad S, Jeske WP, Walenga JM, Aldabbagh A, Iqbal O, Fareed J. Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates. Thrombosis Research. 100: 47-54. PMID 11053616 DOI: 10.1016/S0049-3848(00)00304-2  0.376
2000 Gerbutavicius R, Iqbal O, Messmore H, Hoppensteadt DA, Demir M, Khan E, Bacher P, Fareed J. Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test. Clinical and Applied Thrombosis-Hemostasis. 6: 190-196. PMID 11030523 DOI: 10.1177/107602960000600402  0.367
2000 Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Seminars in Thrombosis and Hemostasis. 26: 5-21. PMID 11011802 DOI: 10.1055/S-2000-9498  0.366
2000 Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K, Sasisekharan R. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proceedings of the National Academy of Sciences of the United States of America. 97: 10365-70. PMID 10984532 DOI: 10.1073/Pnas.97.19.10365  0.311
2000 Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clinical and Applied Thrombosis-Hemostasis. 6: 71-76. PMID 10775025 DOI: 10.1177/107602960000600204  0.379
2000 Stief TW, Kurz J, Doss MO, Fareed J. Singlet oxygen inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood. Thrombosis Research. 97: 473-480. PMID 10704657 DOI: 10.1016/S0049-3848(99)00211-X  0.325
2000 Jeske W, Hoppensteadt DA, Pifarre R, Walenga JM, Fareed J. Mechanism of blood coagulation. Newer aspects of anticoagulant and antithrombotic therapy Intensivmedizin Und Notfallmedizin. 37: 95-122. DOI: 10.1007/978-3-642-51190-5_10  0.365
1999 Jeske W, Walenga JM, Lewis BE, Fareed J. Pharmacology of argatroban. Expert Opinion On Investigational Drugs. 8: 625-54. PMID 15992120 DOI: 10.1517/13543784.8.5.625  0.389
1999 Jeske W, Wolf H, Ahsan A, Fareed J. Pharmacologic profile of certoparin Expert Opinion On Investigational Drugs. 8: 315-327. PMID 15992081 DOI: 10.1517/13543784.8.3.315  0.316
1999 Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clinical and Applied Thrombosis-Hemostasis. 5. PMID 10726038 DOI: 10.1177/10760296990050S111  0.348
1999 Fareed J, Walenga JM, Hoppensteadt DA, Jeske WP, Ahmad S, Lietz H, McKenna R, Messmore HL, Haas S. Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clinical and Applied Thrombosis-Hemostasis. 5. PMID 10726035 DOI: 10.1177/10760296990050S108  0.371
1999 Ahmad S, Walenga JM, Jeske WP, Cella G, Fareed J. Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clinical and Applied Thrombosis-Hemostasis. 5. PMID 10726034 DOI: 10.1177/10760296990050S107  0.404
1999 Ahmad S, Jeske WP, Walenga JM, Hoppensteadt DA, Wood JJ, Herbert JM, Messmore HL, Fareed J. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 5: 259-66. PMID 10726024 DOI: 10.1177/107602969900500410  0.41
1999 Ahmad S, Ahsan A, George M, Iqbal O, Jeske WP, McKenna R, Lewis BE, Walenga JM, Fareed J. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 5: 252-8. PMID 10726023 DOI: 10.1177/107602969900500409  0.307
1999 Fareed J, Hoppensteadt DA, Leya F, Lewis B, Callas D, Wolf H, Bick RL. State-of-the-Art-Review : Thrombogenesis in Myocardial Infarction and Related Syndromes: The Role of Molecular Markers in Diagnosis and Management Clinical and Applied Thrombosis-Hemostasis. 5: 78-91. PMID 10725987 DOI: 10.1177/107602969900500203  0.337
1999 Haas S, Walenga JM, Jeske WP, Fareed J. Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clinical and Applied Thrombosis-Hemostasis. 5: 52-59. PMID 10725984 DOI: 10.1177/107602969900500111  0.352
1999 Kaiser B, Jeske W, Walenga JM, Fareed J. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagulation & Fibrinolysis. 10: 495-501. PMID 10636461 DOI: 10.1097/00001721-199912000-00007  0.374
1999 Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. American Journal of Cardiology. 84: 1391-1395. PMID 10606110 DOI: 10.1016/S0002-9149(99)00582-2  0.346
1999 Hoppensteadt DA, Jeske WP, Walenga JM, Fu K, Yang LH, Ing TS, Herbert J, Fareed J. Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Thrombosis Research. 96: 115-124. PMID 10574589 DOI: 10.1016/S0049-3848(99)00094-8  0.358
1999 Fareed J, Hoppensteadt D, Jeske W, Ahmad S, Bick R. Acquired defects of fibrinolysis associated with thrombosis. Seminars in Thrombosis and Hemostasis. 25: 367-374. PMID 10548070 DOI: 10.1055/S-2007-994940  0.301
1999 Dietrich CP, Paiva JF, Castro RAB, Chavante SF, Jeske W, Fareed J, Gorin PAJ, Mendes A, Nader HB. Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochimica Et Biophysica Acta. 1428: 273-283. PMID 10434045 DOI: 10.1016/S0304-4165(99)00087-2  0.364
1999 Ahmad S, Jeske WP, Wood JJ, Yang LH, Fu K, Walenga JM, Fareed J. Anti-Human Platelet Factor 4-Heparin Antibodies Are Capable Of Activating Primate Platelets As Measured By 14C-Serotonin Release Shock. 11: 36. DOI: 10.1097/00024382-199906001-00124  0.36
1998 Kaiser B, Hoppensteadt DH, Fareed J. Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. Expert Opinion On Investigational Drugs. 7: 1121-1137. PMID 15992020 DOI: 10.1517/13543784.7.7.1121  0.353
1998 Kaiser B, Callas D, Walenga JM, Fareed J. Synthetic and recombinant antithrombin drugs. Expert Opinion On Investigational Drugs. 7: 963-985. PMID 15992009 DOI: 10.1517/13543784.7.6.963  0.363
1998 Yang LH, Hoppensteadt D, Fareed J. Modulation of Vasoconstriction by Clopidogrel and Ticlopidine Thrombosis Research. 92: 83-89. PMID 9792116 DOI: 10.1016/S0049-3848(98)00114-5  0.372
1998 Gurfinkel E, Fareed J, Antman E, Cohen M, Mautner B. Rationale for the Management of Coronary Syndromes With Low-Molecular-Weight Heparins American Journal of Cardiology. 82: 15. PMID 9737475 DOI: 10.1016/S0002-9149(98)00107-6  0.344
1998 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. American Journal of Cardiology. 82. PMID 9737473 DOI: 10.1016/S0002-9149(98)00105-2  0.355
1998 Fareed J, Callas D, Hoppensteadt DA, Walenga JM, Bick RL. ANTITHROMBIN AGENTS AS ANTICOAGULANTS AND ANTITHROMBOTICS: Implications in Drug Development Medical Clinics of North America. 82: 569-586. PMID 9646780 DOI: 10.1016/S0025-7125(05)70011-0  0.383
1998 Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, ... ... Fareed J, et al. Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population Blood. 92: 737-744. DOI: 10.1182/Blood.V92.3.737  0.3
1998 Ahmad S, Ahsan A, Iqbal O, Hoppensteadt DA, Lewis BE, Walenga JM, Fareed J. Pharmacokinetics and Pharmacodynamics of Argatroban as Studied by HPLC and Functional Methods: Implications in the Monitoring and Dosage-Optimizations in Cardiovascular Patients Clinical and Applied Thrombosis-Hemostasis. 4: 243-249. DOI: 10.1177/107602969800400405  0.301
1998 Fareed J. Antithrombin Agents as Anticoagulants and Antithrombotics: Implications in Drug Development Clinical and Applied Thrombosis-Hemostasis. 4: 227-237. DOI: 10.1177/107602969800400403  0.343
1998 Klauser RJ, Hoppensteadt D, Fareed J. Tissue Factor Pathway Inhibitor is a Potent Inhibitor of Plasmin Clinical and Applied Thrombosis-Hemostasis. 4: 114-117. DOI: 10.1177/107602969800400207  0.317
1998 Ahmed Z, Jeske WP, Walenqa JM, Shankey VP, Ahmad S, Fareed J. Aspirin Desensitization Of Thrombin Receptor-Mediated Activation Of Platelets: Dignostic And Clinical Implications.: 1 Shock. 9: 1. DOI: 10.1097/00024382-199806001-00001  0.326
1998 Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes Clinical Chemistry. 44: 1845-1853. DOI: 10.1093/Clinchem/44.8.1845  0.329
1998 Hoppensteadt D, Fareed J, Amiral J, Jeske W, Walenga JM, Lewis B, Wetzel D. Tissue Factor Pathway Inhibitor Release is Specific for Heparin and Low Molecular Weight Heparins. Implications in the Management of Coronary Syndromes Journal of the American College of Cardiology. 31: 53. DOI: 10.1016/S0735-1097(98)80877-2  0.308
1998 Fareed D, Fareed J, Yang L, Hoppensteadt D, Jeske W, Haas S, Messmore H. Hirudin Does Not Prevent Platelet Activation in Heparin Induced Thrombocytopenic Syndromes Journal of the American College of Cardiology. 31: 24. DOI: 10.1016/S0735-1097(98)80756-0  0.339
1997 Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: a developmental perspective. Expert Opinion On Investigational Drugs. 6: 705-733. PMID 15989637 DOI: 10.1517/13543784.6.6.705  0.364
1997 Hoppensteadt DA, Jeske WP, Walenga JM, Fu K, Liu HY, Ing T, Herbert JM, Fareed J. Efficacy Of Pentasaccharide In A Dog Model Of Hemodialysis Thrombosis Research. 88: 159-170. PMID 9361369 DOI: 10.1016/S0049-3848(97)00227-2  0.309
1997 Walenga JM, Fareed J. Current status on new anticoagulant and antithrombotic drugs and devices. Current Opinion in Pulmonary Medicine. 3: 291-302. PMID 9262116 DOI: 10.1097/00063198-199707000-00010  0.349
1997 Kaiser B, Jeske W, Hoppensteadt DH, Walenga JM, Drohan W, Fareed J. In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. Thrombosis Research. 87: 197-204. PMID 9259110 DOI: 10.1016/S0049-3848(97)00119-9  0.382
1997 Yang LH, Fareed J. Vasomodulatory Action Of Clopidogrel And Ticlopidine Thrombosis Research. 86: 479-491. PMID 9219328 DOI: 10.1016/S0049-3848(97)00097-2  0.355
1997 Fu K, Izquierdo R, Vandevender D, Warpeha RL, Wolf H, Fareed J. Topical Application Of Low Molecular Weight Heparin In A Rabbit Traumatic Anastomosis Model Thrombosis Research. 86: 355-361. PMID 9211626 DOI: 10.1016/S0049-3848(97)00080-7  0.341
1997 Jeske W, Fareed J, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Biochemical and Pharmacologic Characteristics of Reviparin, a Low-Molecular-Mass Heparin Seminars in Thrombosis and Hemostasis. 23: 119-128. PMID 9200335 DOI: 10.1055/S-2007-996079  0.377
1997 Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thrombosis Research. 86: 1-36. PMID 9172284 DOI: 10.1016/S0049-3848(97)00042-X  0.306
1997 Walenga JM, Lewis BE, Hoppensteadt DA, Fareed J, Bakbos M. Management of Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis Syndrome Clinical and Applied Thrombosis-Hemostasis. 3. DOI: 10.1177/1076029697003001S08  0.375
1997 Hoppensteadt DA, Kahn S, Fareed J. Factor X Values as a Means to Assess the Extent of Oral Anticoagulation in Patients Receiving Antithrombin Drugs Clinical Chemistry. 43: 1786-1788. DOI: 10.1093/Clinchem/43.9.1786  0.354
1996 Yang LH, Hoppensteadt DA, Iqbal O, Fareed J. Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings. Thrombosis Research. 84: 167-177. PMID 8914216 DOI: 10.1016/0049-3848(96)00173-9  0.308
1996 Doutremepuich C, Azougagh OF, Doutremepuich F, Fareed J. New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity. Thrombosis Research. 83: 217-228. PMID 8840463 DOI: 10.1016/0049-3848(96)00130-2  0.371
1996 Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Preclinical studies on a low molecular weight heparin Thrombosis Research. 81. PMID 8822124 DOI: 10.1016/0049-3848(95)00226-X  0.377
1996 Jeske W, Hoppensteadt D, Callas D, Koza MJ, Fareed J. Pharmacological profiling of recombinant tissue factor pathway inhibitor. Seminars in Thrombosis and Hemostasis. 22: 213-219. PMID 8807720 DOI: 10.1055/S-2007-999011  0.368
1996 Kaiser B, Koza M, Walenga JM, Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood Thrombosis Research. 82: 257-263. PMID 8732629 DOI: 10.1016/0049-3848(96)00072-2  0.389
1996 Fareed J, Jeske W, Callas D, Hoppensteadt D, Walenga J. Modulation of Endothelium by Heparin and Related Polyelectrolytes Clinical and Applied Thrombosis-Hemostasis. 2: 200-208. DOI: 10.1177/107602969600200310  0.323
1996 Kaiser B, Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thrombosis and Haemostasis. 76: 615-620. DOI: 10.1055/S-0038-1650631  0.329
1995 Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin Thrombosis Research. 77: 175-185. PMID 7740509 DOI: 10.1016/0049-3848(95)91623-S  0.343
1995 Fu K, Izquierdo R, Walenga JM, Fareed J. Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model Thrombosis Research. 78: 421-428. PMID 7660358 DOI: 10.1016/0049-3848(95)00075-3  0.344
1995 Lojewski B, Bacher P, Iqbal O, Walenga J, Hoppensteadt D, Leya F, Fareed J. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Seminars in Thrombosis and Hemostasis. 21: 228-239. PMID 7660145 DOI: 10.1055/S-2007-1000398  0.375
1995 Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin. Seminars in Thrombosis and Hemostasis. 21: 212-227. PMID 7660144 DOI: 10.1055/S-2007-1000397  0.37
1995 Jeske W, Lormeau J, Callas D, Iqbal O, Hoppensteadt D, Fareed J. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins. Seminars in Thrombosis and Hemostasis. 21: 193-200. PMID 7660142 DOI: 10.1055/S-2007-1000395  0.361
1995 Iyer L, Adam M, Amiral J, Fareed J, Bermes E. Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudin. Seminars in Thrombosis and Hemostasis. 21: 184-192. PMID 7660141 DOI: 10.1055/S-2007-1000394  0.308
1995 Callas D, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Seminars in Thrombosis and Hemostasis. 21: 177-183. PMID 7660140 DOI: 10.1055/S-2007-1000393  0.352
1995 Callas D, Bacher P, Fareed J. Studies on the thrombogenic effects of recombinant tissue factor. In vivo versus ex vivo findings. Seminars in Thrombosis and Hemostasis. 21: 166-176. PMID 7660139 DOI: 10.1055/S-2007-1000392  0.308
1995 Iyer L, Fareed J. Determination of specific activity of recombinant hirudin using a thrombin titration method Thrombosis Research. 78: 259-263. PMID 7631307 DOI: 10.1016/0049-3848(95)90877-I  0.327
1995 Alban S, Jeske W, Welzel D, Franz G, Fareed J. Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate. Thrombosis Research. 78: 201-10. PMID 7631300 DOI: 10.1016/0049-3848(95)00049-W  0.365
1995 Paiva JF, Santos EA, Jeske W, Fareed J, Nader HB, Dietrich CP. A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins. Comparative Biochemistry and Physiology. Part a, Physiology. 111: 495-9. PMID 7614042 DOI: 10.1016/0300-9629(94)00021-K  0.368
1995 Jeske W, Hoppensteadt D, Klauser R, Kammereit A, Eckenberger P, Haas S, Wyld P, Fareed J. Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels. Blood Coagulation & Fibrinolysis. 6: 119-124. PMID 7605876 DOI: 10.1097/00001721-199504000-00005  0.308
1995 Fareed J, Hoppensteadt D, Iyer L, Koza M, Walenga JM, Bermes E. Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. Advances in Experimental Medicine and Biology. 369: 99-110. PMID 7598021 DOI: 10.1007/978-1-4615-1957-7_10  0.302
1995 Callas DD, Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors: Implications in anticoagulant and thrombolytic therapy Thrombosis Research. 78: 457-460. PMID 7544924 DOI: 10.1016/0049-3848(95)99612-C  0.313
1995 Arcelus JI, Caprini JA, Hoffman KN, Traverso CI, Hoppensteadt D, Fareed J. Modifications of plasma levels of tissue factor pathway inhibitor and endothelin-1 induced by a reverse Trendelenburg position: influence of elastic compression--preliminary results. Journal of Vascular Surgery. 22: 568-572. PMID 7494357 DOI: 10.1016/S0741-5214(95)70039-0  0.323
1995 Fareed J, Callas DD, Hoppensteadt D, Jeske W, Walenga JM. Section Review—Cardiovascular & Renal: Recent Developments in Antithrombotic Agents Expert Opinion On Investigational Drugs. 4: 389-412. DOI: 10.1517/13543784.4.5.389  0.308
1995 Callas DD, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic Compromise by Synthetic and Recombinant Thrombin Inhibitors: Implications in the Treatment of Thrombotic Disorders Clinical and Applied Thrombosis-Hemostasis. 1: 114-124. DOI: 10.1177/107602969500100203  0.313
1995 Fareed J, Bick RL, Hoppensteadt DA, Bermes EW. Molecular Markers of Hemostatic Activation: Applications in the Diagnosis of Thrombosis and Vascular and Thrombotic Disorders Clinical and Applied Thrombosis-Hemostasis. 1: 87-102. DOI: 10.1177/107602969500100201  0.31
1995 Desai UR, Hoppensteadt D, Fareed J, Linhardt RJ. Measurement of the Antithrombin III Binding Sites in Low Molecular Weight Heparins by 13C NMR and Capillary Electrophoresis Pharmacy and Pharmacology Communications. 1: 349-353. DOI: 10.1111/J.2042-7158.1995.Tb00438.X  0.329
1995 Dries DJ, Hoppensteadt D, Walenga JM, Fareed J. Molecular Markers Of Coagulation, Fibrinolysis And Vascular Activation In Trauma Patients. Critical Care Medicine. 23. DOI: 10.1097/00003246-199501001-00412  0.304
1995 Fareed J, Bick RL, Hoppensteadt DA, Walenga JM, Messmore HL, Bermes EW. Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. Clinics in Laboratory Medicine. 15: 39-61. DOI: 10.1016/S0272-2712(18)30343-3  0.302
1995 Fareed J, Jeske W. Pharmacology of Synthetic and Biotechnology-Derived Homologues and Analogues of Heparin Pharmacological Research. 31: 65-87. DOI: 10.1016/1043-6618(95)87454-2  0.36
1994 Fareed J, Hoppensteadt D, Walenga JM, Bick RL. Current trends in the development of anticoagulant and antithrombotic drugs Medical Clinics of North America. 78: 713-731. PMID 8170266 DOI: 10.1016/S0025-7125(16)30154-7  0.358
1994 Linhardt RJ, Desai UR, Liu J, Pervin A, Hoppensteadt D, Fareed J. Low molecular weight dermatan sulfate as an antithrombotic agent. Structure-activity relationship studies. Biochemical Pharmacology. 47: 1241-52. PMID 8161353 DOI: 10.1016/0006-2952(94)90396-4  0.326
1994 Pinhal MAS, Walenga JM, Jeske W, Hoppensteadt D, Dietrich CP, Fareed J, Nader HB. Antithrombotic agents stimulate the synthesis and modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells. Thrombosis Research. 74: 143-153. PMID 8029815 DOI: 10.1016/0049-3848(94)90007-8  0.337
1994 Kijowski R, Hoppensteadt D, Walenga J, Borris L, Lassen MR, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin Thrombosis Research. 74: 53-64. PMID 8029808 DOI: 10.1016/0049-3848(94)90035-3  0.37
1994 Kijowski R, Hoppensteadt D, Jeske W, Fareed J. Protamine sulfate neutralization of the anticoagulant activity of aprosulate, a synthetic sulfated lactobionic acid amide Thrombosis Research. 73: 349-359. PMID 8016819 DOI: 10.1016/0049-3848(94)90030-2  0.375
1994 Kaiser B, Callas D, Hoppensteadt D, Mallinowska K, Fareed J. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems. Thrombosis Research. 73: 327-335. PMID 8016817 DOI: 10.1016/0049-3848(94)90028-0  0.362
1994 Kaiser B, Jeske W, Hoppensteadt D, Fareed J. Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma Thrombosis Research. 76: 561-568. PMID 7900103 DOI: 10.1016/0049-3848(94)90285-2  0.342
1994 Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans. Thrombosis Research. 75: 609-616. PMID 7831680 DOI: 10.1016/0049-3848(94)90173-2  0.338
1994 Walenga JM, Fareed J. Automation and quality control in the coagulation laboratory. Clinics in Laboratory Medicine. 14: 709-728. DOI: 10.1016/S0272-2712(18)30353-6  0.362
1993 lyer L, Koza M, Iqbal O, Calabria R, Fareed J. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs Thrombosis Research. 69: 259-269. PMID 8475476 DOI: 10.1016/0049-3848(93)90023-H  0.32
1993 Callas DD, Ahsan A, Iqbal O, Fareed J. Molecular weight and biochemical profile of a chemically modified heparin derivative, Suleparoide® Thrombosis Research. 69: 369-376. PMID 8470058 DOI: 10.1016/0049-3848(93)90036-N  0.362
1993 Iyer L, Shavit J, Koza M, Calabria R, Moran S, Fareed J. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs Thrombosis Research. 69: 59-70. PMID 8465275 DOI: 10.1016/0049-3848(93)90003-7  0.337
1993 Bacher P, Iqbal O, Lojewski B, Walenga JM, Leya F, Fareed J. A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model. Thrombosis Research. 70: 295-306. PMID 8392758 DOI: 10.1016/0049-3848(93)90102-T  0.354
1993 Bacher P, Walenga JM, Iqbal O, Bajusz S, Breddin K, Fareed J. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models Thrombosis Research. 71: 251-263. PMID 8236155 DOI: 10.1016/0049-3848(93)90195-T  0.337
1992 Ofosu FA, Fareed J, Smith LM, Anvari N, Hoppensteadt D, Blajchman MA. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. Febs Journal. 203: 121-125. PMID 1730217 DOI: 10.1111/J.1432-1033.1992.Tb19836.X  0.347
1992 Kaiser B, Fareed J, Hoppensteadt D, Birdsong B, Walenga JM, Markwardt F. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Thrombosis Research. 65: 157-164. PMID 1579892 DOI: 10.1016/0049-3848(92)90235-3  0.36
1992 Fareed J, Bacher P, Messmore HL, Walenga JM, Hoppensteadt DA, Strano A, Pifarre R. Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs Progress in Cardiovascular Diseases. 34: 379-398. PMID 1579631 DOI: 10.1016/0033-0620(92)90006-L  0.322
1992 Walenga JM, Hoppensteadt D, Fareed J, Pifarré R. Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers The Annals of Thoracic Surgery. 53: 844-850. PMID 1570981 DOI: 10.1016/0003-4975(92)91448-I  0.372
1992 Racanelli AA, Fareed J. Neutralization of the antithrombotic effects of heparin and fraxiparinR by protamine sulfate Thrombosis Research. 68: 211-222. PMID 1471069 DOI: 10.1016/0049-3848(92)90079-P  0.362
1992 Racanelli A, Fareed J. Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine. Thrombosis Research. 67: 263-273. PMID 1332215 DOI: 10.1016/0049-3848(92)90145-Z  0.32
1992 Bacher P, Welzel D, Iqbal O, Hoppensteadt D, Callas D, Walenga JM, Fareed J. The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thrombosis Research. 66: 151-158. PMID 1329252 DOI: 10.1016/0049-3848(92)90185-D  0.311
1992 Hoppensteadt D, Walenga JM, Fareed J. Low Molecular Weight Heparins Drugs & Aging. 2: 406-422. PMID 1327312 DOI: 10.2165/00002512-199202050-00005  0.321
1991 Walenga JM, Hoppensteadt D, Koza M, Wallock M, Pifarre R, Fareed J. Laboratory Assays for the Evaluation of Recombinant Hirudin Pathophysiology of Haemostasis and Thrombosis. 21: 49-63. PMID 1894197 DOI: 10.1159/000216263  0.313
1991 Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins Thrombosis Research. 61: 49-62. PMID 1658970 DOI: 10.1016/0049-3848(91)90403-J  0.394
1991 Rao GH, Fareed J, White JG. Influence of heparins on inositol 1,4,5-trisphosphate-induced calcium mobilization in permeabilized human platelets Biochemical Medicine and Metabolic Biology. 45: 171-180. DOI: 10.1016/0885-4505(91)90018-G  0.338
1990 Reddy VB, Kowal-Vern A, Hoppensteadt DA, Kumar A, Walenga JM, Fareed J, Harold RS. Global and molecular hemostatic markers in acute myeloid leukemia. American Journal of Clinical Pathology. 94: 397-403. PMID 2220667 DOI: 10.1093/Ajcp/94.4.397  0.374
1990 Brace LD, Fareed J. Heparin-induced platelet aggregation. II. Dose/response relationships for two low molecular weight heparin fractions (CY 216 and CY 222) Thrombosis Research. 59: 1-14. PMID 2169074 DOI: 10.1016/0049-3848(90)90266-F  0.369
1990 Linhardt RJ, Loganathan D, al-Hakim A, Wang HM, Walenga JM, Hoppensteadt D, Fareed J. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. Journal of Medicinal Chemistry. 33: 1639-45. PMID 2160537 DOI: 10.1021/Jm00168A017  0.325
1990 Hoppensteadt D, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparin sulfate and heparin Thrombosis Research. 60: 191-200. PMID 2084948 DOI: 10.1016/0049-3848(90)90180-K  0.399
1989 Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J. Antithrombotic activity of recombinant hirudin in the rat: A comparative study with heparin Thrombosis Research. 54: 435-445. PMID 2772867 DOI: 10.1016/0049-3848(89)90213-2  0.337
1989 Fareed J, Walenga JM, Cornelli U. Antithrombotic drugs in pelvic surgery. Seminars in Thrombosis and Hemostasis. 15: 230-232. PMID 2665091 DOI: 10.1055/S-2007-1002710  0.302
1989 Doutremepuich C, Guyot M, Lalanne MC, Deharo E, Walenga JM, Fareed J. Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects. Thrombosis Research. 55: 419-426. PMID 2554524 DOI: 10.1016/0049-3848(89)90050-9  0.357
1989 Fareed J, Walenga JM, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Annals of the New York Academy of Sciences. 556: 333-53. PMID 2544128 DOI: 10.1111/J.1749-6632.1989.Tb22515.X  0.333
1989 Hoppensteadt D, Racanelli A, Walenga J, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Seminars in Thrombosis and Hemostasis. 15: 378-385. PMID 2530633 DOI: 10.1055/S-2007-1002734  0.318
1989 Messmore HL, Griffin B, Fareed J, Coyne E, Seghatchian J. In Vitro Studies of the Interaction of Heparin, Low Molecular Weight Heparin and Heparinoids with Platelets Annals of the New York Academy of Sciences. 556: 217-232. PMID 2472085 DOI: 10.1111/J.1749-6632.1989.Tb22505.X  0.394
1988 Walenga JM, Petitou M, Samama M, Fareed J, Choay J. Importance of a 3-0-sulfate group in a heparin pentasaccharide for antithrombotic activity Thrombosis Research. 52: 553-563. PMID 3232125 DOI: 10.1016/0049-3848(88)90128-4  0.331
1988 Coyne E, Walenga JM, Fareed J. Aggregates in heparin. Journal of Pharmaceutical Sciences. 77: 818-819. PMID 3225781 DOI: 10.1002/Jps.2600770923  0.321
1988 Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thrombosis Research. 51: 23-33. PMID 3166242 DOI: 10.1016/0049-3848(88)90279-4  0.386
1988 Suarez CR, Gonzalez J, Menendez C, Fareed J, Fresco R, Walenga J. Neonatal and maternal platelets: activation at time of birth. American Journal of Hematology. 29: 18-21. PMID 2972197 DOI: 10.1002/Ajh.2830290105  0.368
1988 Fareed J, Walenga JM, Racanelli A, Hoppensteadt D, Huan X, Messmore HL. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis. 18: 33-47. PMID 2840373 DOI: 10.1159/000215866  0.347
1988 Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis. 18: 3-15. PMID 2840372 DOI: 10.1159/000215861  0.406
1988 Choate JJ, Domenico DR, McGraw TP, Fareed J, Molnar Z, Schumacher HR. Diagnosis of acute megakaryoblastic leukemia by flow cytometry and immunoalkaline phosphatase techniques. Utilization of new monoclonal antibodies. American Journal of Clinical Pathology. 89: 247-53. PMID 2829618 DOI: 10.1093/Ajcp/89.2.247  0.301
1987 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thrombosis Research. 46: 187-198. PMID 3603420 DOI: 10.1016/0049-3848(87)90280-5  0.38
1986 Brace LD, Issleib S, Fareed J. Letter to the editors-in-chiefHeparin-induced platelet aggregation is inhibited by antagonists of the thronboxane pathway Thrombosis Research. 44. PMID 3798406 DOI: 10.1016/0049-3848(86)90017-4  0.324
1986 Fareed J, Walenga JM, Svendsen LG, Bermes EW. Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usage. Seminars in Thrombosis and Hemostasis. 12: 310-317. PMID 3787268 DOI: 10.1055/S-2007-1003572  0.355
1986 Brace LD, Fareed J. Heparin-induced platelet aggregation: Dose/response relationships for a low molecular weight heparin derivative (pk 10169) and its subfractions Thrombosis Research. 42: 769-782. PMID 3726798 DOI: 10.1016/0049-3848(86)90113-1  0.389
1986 Brace LD, Fareed J, Tomeo J, Issleib S. Biochemical and pharmacological studies on the interaction of PK 10169 and its subfractions with human platelets. Haemostasis. 16: 93-105. PMID 3710299 DOI: 10.1159/000215279  0.4
1986 Fareed J, Walenga J, Baker W, Hayes A, Hoppensteadt D. Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transition. Seminars in Thrombosis and Hemostasis. 12: 102-109. PMID 2943019 DOI: 10.1055/S-2007-1003542  0.308
1986 Fareed J, Walenga JM. Biochemical and pharmacological considerations in the development of heparin and its depolymerized derivatives The Medical Journal of Australia. 144. DOI: 10.5694/J.1326-5377.1986.Tb112379.X  0.304
1985 Brace LD, Issleib S, Fareed J. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. Thrombosis Research. 39: 533-539. PMID 4049330 DOI: 10.1016/0049-3848(85)90176-8  0.337
1985 Brace L, Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Seminars in Thrombosis and Hemostasis. 11: 190-198. PMID 4035366 DOI: 10.1055/S-2007-1004374  0.384
1985 Fareed J, Kumar A, Rock A, Walenga J, Davis P. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions. Seminars in Thrombosis and Hemostasis. 11: 138-154. PMID 4035364 DOI: 10.1055/S-2007-1004371  0.4
1985 Emanuele R, Fareed J, Walenga J, Hoppensteadt D, Baker W. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions. Seminars in Thrombosis and Hemostasis. 11: 121-128. PMID 4035363 DOI: 10.1055/S-2007-1004368  0.323
1985 Walenga J, Bara L, Samama M, Fareed J. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Seminars in Thrombosis and Hemostasis. 11: 100-107. PMID 4035361 DOI: 10.1055/S-2007-1004365  0.308
1985 Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Seminars in Thrombosis and Hemostasis. 11: 155-175. PMID 3929386 DOI: 10.1055/S-2007-1004372  0.368
1985 Fareed J. Heparin, Its Fractions, Fragments and Derivatives Some Newer Perspectives Seminars in Thrombosis and Hemostasis. 11: 1-9. PMID 3919446 DOI: 10.1055/S-2007-1004350  0.333
1985 Hoppensteadt D, Walenga J, Fareed J. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. Seminars in Thrombosis and Hemostasis. 11: 112-120. PMID 3898369 DOI: 10.1055/S-2007-1004367  0.376
1985 Fareed J, Walenga J, Williamson K, Emanuele R, Kumar A, Hoppensteadt D. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Seminars in Thrombosis and Hemostasis. 11: 56-74. PMID 3883500 DOI: 10.1055/S-2007-1004360  0.374
1985 Walenga J, Fareed J, Hoppensteadt D. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169). Seminars in Thrombosis and Hemostasis. 11: 17-25. PMID 3883497 DOI: 10.1055/S-2007-1004353  0.409
1985 Fareed J, Walenga JM, Hoppensteadt DA, Messmore HL. Studies on the profibrinolytic actions of heparin and its fractions. Seminars in Thrombosis and Hemostasis. 11: 199-207. PMID 3875899 DOI: 10.1055/S-2007-1004375  0.339
1985 Walenga JM, Fareed J, Hoppensteadt D, Emanuele RM. In Vitro Evaluation of Heparin Fractions: Old vs. New Methods Critical Reviews in Clinical Laboratory Sciences. 22: 361-389. PMID 2936571 DOI: 10.3109/10408368509165791  0.385
1984 Walenga J, Hoppensteadt D, Emanuele R, Fareed J. Performance characteristics of a simple radioimmunoassay for fibrinopeptide A. Seminars in Thrombosis and Hemostasis. 10: 219-227. PMID 6515418 DOI: 10.1055/S-2007-1004427  0.315
1984 Prinz RA, Fareed J, Rock A, Squillaci G, Wallenga J. Platelet activation by human pancreatic fluid Journal of Surgical Research. 37: 314-319. PMID 6482425 DOI: 10.1016/0022-4804(84)90195-1  0.37
1984 Fareed J, Moncada R, Messmore H, Walenga J, Hoppensteadt D, Wehrmacher W. Molecular markers of contrast media-induced adverse reactions. Seminars in Thrombosis and Hemostasis. 10: 306-328. PMID 6393351 DOI: 10.1055/S-2007-1004437  0.335
1984 Amiral J, Walenga J, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Seminars in Thrombosis and Hemostasis. 10: 228-242. PMID 6393350 DOI: 10.1055/S-2007-1004428  0.353
1984 Messmore H, Walenga J, Fareed J. Molecular markers of platelet activation. Seminars in Thrombosis and Hemostasis. 10: 264-269. PMID 6240115 DOI: 10.1055/S-2007-1004431  0.352
1984 Parvez Z, Moncada R, Fareed J, Messmore HL. Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures. Investigative Radiology. 19: 208-211. DOI: 10.1097/00004424-198405000-00010  0.369
1983 Fareed J, Bick RL, Squillaci G, Walenga JM, Bermes EW. Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clinical Chemistry. 29: 1641-1658. DOI: 10.1093/Clinchem/29.9.1641  0.374
1983 Fareed J, Walenga J, Bick R, Bermes E, Messmore H. Impact of automation on the quantitation of low molecular weight markers of hemostatic defects. Seminars in Thrombosis and Hemostasis. 9: 355. DOI: 10.1055/S-2007-1005036  0.393
1983 Walenga J, Fareed J, Messmore H. Newer avenues in the monitoring of antithrombotic therapy: the role of automation. Seminars in Thrombosis and Hemostasis. 9: 346-354. DOI: 10.1055/S-2007-1005035  0.355
1982 Sache E, Maillard M, Bertrand H, Maman M, Kunz M, Choay J, Fareed J, Messmore H. Studies on a highly active anticoagulant fraction of high molecular weight isolated from porcine sodium heparin. Thrombosis Research. 25: 443-458. PMID 7112506 DOI: 10.1016/0049-3848(82)90086-X  0.352
1982 Parvez Z, Moncada R, Fareed J, Messmore HL. Effects of nonionic contrast media (CM) on the components of coagulation and complement systems. Investigative Radiology. 18: 279-284. PMID 6618818 DOI: 10.1097/00004424-198305000-00012  0.363
1981 Sache E, Choay J, Fareed J. Studies On A Highly Potent Anticoagulant Anionic High Molecular Weight Fraction Isolated From Porcine Heparin Annals of the New York Academy of Sciences. 370: 627-643. PMID 6943973 DOI: 10.1111/J.1749-6632.1981.Tb29769.X  0.303
Show low-probability matches.